

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Cost-effectiveness of implementing HIV and HIV/syphilis dual testing among key populations in Viet Nam: a modeling analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-056887
Article Type:	Original research
Date Submitted by the Author:	04-Oct-2021
Complete List of Authors:	Coomes, David; University of Washington, Department of Epidemiology; University of Washington, Department of Global Health Green, Dylan; University of Washington, Department of Epidemiology; University of Washington, Department of Global Health Barnabas, Ruanne; University of Washington, Department of Global Health; University of Washington, Department of Medicine Sharma, Monisha; University of Washington, Department of Global Health Barr-DiChiara, Magdalena; World Health Organization, Department of Global Programmes of HIV, Hepatitis and HIV Jamil, Muhammad; World Health Organization, Department of Global Programmes of HIV, Hepatitis and HIV Baggaley, R; World Health Organization, Department of Global Programmes of HIV, Hepatitis and HIV Owiredu, Morkor Newman; World Health Organization, Department of Global Programmes of HIV, Hepatitis and HIV Macdonald, Virginia; World Health Organization, Headquarters Nguyen, Van Thi Thuy; World Health Organization, Viet Nam Country Office Vo, Son; Government of Viet Nam Ministry of Health, Viet Nam Authority for HIV/AIDS Prevention and Control Taylor, Melanie; Centers for Disease Control and Prevention, Division of STD Prevention Wi, Teodora; World Health Organization, Department of Reproductive Health and Research Johnson, Cheryl; World Health Organization, Headquarters; London School of Hygiene & Tropical Medicine, Clinical Research Department Drake, Alison L.; University of Washington, Department of Global Health; University of Washington, Department of Epidemiology
Keywords:	HEALTH ECONOMICS, HIV & AIDS < INFECTIOUS DISEASES, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
21 **Cost-effectiveness of implementing HIV and HIV/syphilis dual testing among key populations in Viet Nam: a**
3
42 **modeling analysis**

5
63 David Coomes^{1,2}, Dylan Green^{1,2}, Ruanne Barnabas^{1,2,3}, Monisha Sharma², Magdalena Barr-DiChiara⁴,
7
84 Muhammad S. Jamil⁴, Rachel Baggaley⁴, Morkor Newman Owiredu⁴, Virginia Macdonald⁵, Van Nguyen⁶, Son
95 Vo Hai⁷, Melanie M. Taylor^{4,8}, Teodora E Wi⁹, Cheryl Johnson^{5,10}, Alison L. Drake^{1,2§}

- 10
11
12 1. University of Washington, Department of Epidemiology, Seattle, WA, USA
13
14 2. University of Washington, Department of Global Health, Seattle, WA, USA
15
16 3. University of Washington, Department of Medicine, Seattle, WA, USA
17
18 4. Department of Global Programmes of HIV, Hepatitis and HIV, World Health Organization, Geneva,
19
20 Switzerland
21
22 5. Headquarters, World Health Organization, Geneva, Switzerland
23
24 6. Viet Nam Country Office, World Health Organization, Hanoi, Viet Nam
25
26 7. Viet Nam Authority for HIV/AIDS Prevention and Control, Ministry of Health, Hanoi, Viet Nam
27
28 8. Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
29
30 9. Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland
31
32 10. Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United
33
34 Kingdom

35
36 § Corresponding author: Alison L. Drake

37
38 325 9th Avenue
39
40 Box 359909
41
42 Seattle, WA 98195, USA
43
44 Phone: 1-206-543-5847
45
46 Email: adrake2@uw.edu

47
48
49 Disclaimer: The views expressed in this manuscript are those of the authors and do not necessarily represent the
50
51 official position of the World Health Organization or the United States Centers for Disease Control
52
53

54
55
56 Word count: 3,652

57
58
59 Abstract word count: 247

60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Keywords: HIV testing, syphilis testing, key populations, 95-95-95

ABSTRACT

Objectives

Key populations, including sex workers, men who have sex with men, and people who inject drugs, have a high risk of HIV and sexually transmitted infections (STIs). We assessed the health and economic impacts of different HIV and syphilis testing strategies among three key populations in Viet Nam using a dual HIV/syphilis rapid diagnostic test (RDT).

Setting

We used the Spectrum AIDS Impact Model to simulate the HIV epidemic in key populations in Viet Nam and evaluated five testing scenarios. We used a 15-year time horizon and all costs are from the provider's perspective.

Participants

We include the entire population of Viet Nam in the model.

Interventions

We model five testing scenarios among key populations: 1) annual testing with an HIV rapid diagnostic test (RDT), 2) annual testing with a dual RDT, 3) biannual testing using dual RDT and HIV RDT, 4) biannual testing using HIV RDT, and 5) biannual testing using dual RDTs.

Primary and secondary outcome measures

The primary outcome is incremental cost-effectiveness ratios (ICERS). Secondary outcomes include HIV and syphilis cases and costs for each proposed intervention.

Results

Annual testing using a dual HIV/syphilis RDT was cost saving and averted 3,206 HIV cases and treated 7,719 syphilis cases compared to baseline over 15 years. Biannual testing using one dual test and one HIV RDT, or two dual tests both averted an additional 875 HIV cases and were cost-effective (\$1,024 and \$2,518 per DALY averted, respectively). Annual or biannual HIV testing using HIV RDTs and separate syphilis tests were more costly and less effective than using one or two dual RDTs.

1
2 **Conclusions**

3
4 Annual or biannual HIV and syphilis testing using dual RDTs among key populations can be cost-effective and
5
6 support countries in reaching global reduction goals for HIV and syphilis.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STRENGTHS AND LIMITATIONS OF THIS STUDY

- Strength: Our model presents novel cost-effectiveness estimates for the use of dual HIV/syphilis testing in key populations that can inform health planners
- Strength: We include five testing scale up scenarios using both HIV RDT and dual HIV/syphilis RDT
- Strength: Our model is informed by demographic, behavioral, and biological data from government sources, surveys, surveillance, publicly available reports, databases, and peer-reviewed literature
- Limitation: We made some assumptions regarding the timing and uptake of HIV and syphilis testing among key populations that may be inaccurate.
- Limitation: Our model assumes that increased syphilis testing and treatment will not impact syphilis prevalence, however, it is unknown whether increased testing will reduce or increase syphilis prevalence.

INTRODUCTION

Key populations, including people who inject drugs (PWID), men who have sex with men (MSM), sex workers (SW), and transgender populations, are at higher risk of acquiring both HIV and syphilis. HIV incidence is significantly higher among key populations in all regions compared to the general population; however, differences vary substantially by region and by key population.[1] While key populations represent 25% of new HIV cases in sub-Saharan Africa, they represent 80% of new HIV cases in the rest of the world.[2] Recent data suggests syphilis incidence, while remaining prevalent in low- and middle-income countries (LMIC), is increasing among key populations, particularly MSM.[1, 3, 4] World Health Organization (WHO) HIV testing guidelines recommend HIV retesting at least annually for key populations and more frequent testing (3-6 months) for those with high ongoing risk.[5] WHO guidelines for syphilis screening depend on population and setting. Rapid diagnostic tests (RDTs) are increasingly being used to screen for syphilis in some settings, yet laboratory-based testing remains common,[6] leaving many key populations unreached by syphilis testing. With the introduction of prequalified dual HIV/syphilis RDTs, and the recent WHO recommendation to offer dual HIV/syphilis testing in antenatal care (ANC) settings,[7] it is important to consider how further integration and expansion of dual HIV/syphilis testing could benefit key populations.

Since 2015, WHO has recommended immediate initiation of antiretroviral therapy (ART) for all people living with HIV (PLHIV) [8] and the United Nations 95-95-95 targets aim to diagnose 95% of PLHIV, provide 95% of PLHIV with ART, and ensure 95% PLHIV on ART are virally suppressed.[9] Despite progress towards these goals – in 2019 81% of PLHIV knew their HIV status and 67% were on ART – this progress is uneven; only 2/3 of key populations are aware of their HIV status.[2] While key populations lag behind the general population in all phases of testing, linkage to treatment, and viral suppression, the largest gap exists in testing.[10] WHO has also developed a global strategy on sexually transmitted infections (STIs) which aims for a 90% reduction in syphilis incidence by 2030, and for 70% of key populations to have access to STI and HIV services, including prevention, testing, and treatment.[11] Increased syphilis testing and treatment may reduce syphilis burden among key and general populations, as well as HIV incidence since early symptomatic syphilis increases risks of HIV

acquisition and transmission.[3] Currently, the frequency of syphilis testing recommended by WHO is based on local epidemics; however, the optimal frequency for syphilis testing among key populations is unknown.

In Viet Nam, the national HIV prevalence is <1% in the general population, and significantly higher in key populations, with prevalence ranging between 3-13% among PWID, MSM, and FSW. Similarly, syphilis prevalence among MSM (6.7%) and FSW (2.1%) are also higher than the general population (0.3%).[12] With budgetary constraints in HIV and STI programs, and the health sector, identifying cost-effective strategies for targeted HIV and syphilis testing among high risk groups in Viet Nam is crucial to inform policymakers seeking to optimize resource allocation to maximize population health. We modeled the health impacts and costs associated with varying frequencies of HIV and syphilis testing for key populations, using test scenarios that include a dual HIV/syphilis RDT.

METHODS

Settings and Populations

We modeled three key populations: MSM, PWID, and FSW (and their clients) in Viet Nam, using national level HIV prevalence and syphilis prevalence estimates for each key population (**Table 1**).

Table 1. Model parameters for Spectrum input and cost-effectiveness analysis of HIV and syphilis testing scale up among key populations in Viet Nam. ^a = 2018 Viet Nam HIV Sentinel Surveillance. ^b = 2019 Viet Nam HIV Sentinel Surveillance. * = Spectrum model prior. ** = assumed. *** = Based on information from in-country source.

Model parameter	Value
HIV Prevalence	
MSM (incl. TGW) ^a	10.8%
PWID ^b	12.7%
FSW ^a	3.6%
Syphilis Prevalence[12]	
MSM (incl. TGW)	6.7%
PWID	0.3%
FSW	2.1%
Baseline syphilis test acceptance	
MSM (incl. TGW)[45],[46],[14]	27%
PWID[15]	16%
FSW[16],[47]	35%

1	Syphilis DALYs averted[48]	
2		
3	DALYs averted per syphilis case treated	0.04
4	ART	
5	2019 Coverage***	70%
6	Annual Scale-Up**	4.8%
7	Transmission Reduction Efficacy*	70%
8	Mortality Reduction Efficacy*	80%
9		
10		
11	Other Prevention	
12	Condom Use**	50%
13	Condom Efficacy*	80%
14	PrEP Coverage (MSM incl. TGW)**	5%
15	PrEP Efficacy*	90%
16	PrEP Adherence*	80%
17		
18		
19	Costs***	
20	HIV Lay Test†	\$4.50
21	Syphilis RPR†	\$6.28
22	HIV/Syphilis Dual Test†	\$6.50
23	ART‡	\$285
24	Syphilis Treatment	\$6.50
25	Time Horizon	2020 - 2035
26	Discount Rate	3%
27		
28		

129 † Testing costs include labor, incentives, travel costs, and test kits. Primary cost driver between tests is the cost of the test kit.

130 ‡ ART cost includes labor, laboratory monitoring costs, ARVs, and other recurring costs.

131 * MSM=men who have sex with men, FSW=female sex workers, PWID=people who inject drugs, TGW=transgender women,
132 ART=antiretroviral therapy, PrEP=pre-exposure prophylaxis, syphilis RPR=syphilis rapid plasma regain.

133
134

135 Model

136
137 We used a deterministic, compartmental model to simulate the HIV epidemic in key populations from 2020-2035
138 using the AIDS Impact Model within the Spectrum software package (v 5.76). The model estimates annual HIV
139 incidence, AIDS mortality, and disability. We simulated the impact of increasing HIV testing frequency using the
140 Goals model within Spectrum, as previously described.[13] Briefly, the model is age- and sex-stratified with
141 compartments for MSM, PWID, FSW and their clients, and low- and medium-risk heterosexuals.¹ The model was
142 parameterized with demographic, behavioral, and biological data from government sources, surveys, surveillance,
143 publicly available reports, databases, and peer-reviewed literature. To estimate syphilis burden, we used
144
145
146
147
148
149
150
151
152
153
154
155

156 ¹ Low-risk heterosexuals are those in stable couples while medium-risk heterosexuals are those that engage in casual sex but are not
157 in a high-risk group (high risk groups: MSM, FSW, PWID).

158
159
160

population size estimates from the Goals model and population-specific estimates of prevalence;^[12] we estimate the number of persons tested positive and treated for syphilis infection under each scenario. This model assumes that syphilis testing and treatment does not impact syphilis prevalence. For both HIV and syphilis, disability-adjusted life years (DALYs) are calculated for each scenario. Model key parameters are shown in **Table 1**.

Costs

Cost inputs include cost per HIV test, initial syphilis test (rapid plasma reagin (RPR)), and the dual HIV/syphilis RDT. We used local data on the personnel, commodities, and transport costs associated with lay testing and estimate costs (**Table 1**). ART costs include personnel, commodities, clinical follow-up, and laboratory monitoring. This analysis includes the costs of intervention delivery and treatment (penicillin and ART) but does not consider additional averted sequelae costs such as the treatment of opportunistic infections due to uncontrolled HIV. All costs are from the provider's perspective and reported in 2019 US dollars.

Scenarios

Our baseline scenario estimates annual HIV testing based on current WHO recommendations,^[5] and syphilis testing based on observed uptake. In the baseline scenario, we assume 50% of individuals in key populations test annually for HIV, and syphilis testing with RPR occurs at rates specific to each key population (**Table 2**).^[14–16] We considered alternative scenarios with varying testing frequency and test type (separate HIV and syphilis RPR, or a combined dual syphilis/HIV RDT) among key populations from 2020 to 2035. Scenarios modeled include: **1)** annual HIV testing with RDT and baseline syphilis RPR testing, **2)** annual testing with dual RDT, **3)** biannual testing (2 times per year), first with dual RDT and then with HIV RDT, **4)** biannual HIV testing with RDT and baseline syphilis RPR testing, and **5)** biannual testing with dual RDT (**Table 2**). We assumed 75% test acceptance for the first test in all scenarios except baseline, and 90% of those who accepted the first test would accept the second test in all scenarios that include biannual testing.

Table 2: HIV/syphilis testing scenarios among key populations in Viet Nam. The table cells show the proportion of key populations in Viet Nam that receive each test per year. If not specified, the proportion refers to all key populations.

Scenario	Proportion of key population receiving HIV or syphilis testing per year			
	1 HIV test	2 HIV tests	1 syphilis test	2 syphilis tests
Baseline	50%	-	35% (FSW), 27% (MSM), 16% (PWID)	-
1. One HIV RDT	75%	-	35% (FSW), 27% (MSM), 16% (PWID)	-
2. One Dual HIV/syphilis RDT	75%		75%	-
3. One HIV RDT & One Dual HIV/syphilis RDT	75%	68%	75%	-
4. Two HIV RDTs	75%	68%	35% (FSW), 27% (MSM), 16% (PWID)	-
5. Two Dual HIV/syphilis RDT	75%	68%	75%	68%

* MSM=men who have sex with men, FSW=female sex workers, PWID=people who inject drugs, RDT=rapid diagnostic test.

We modeled increases in testing coverage by adjusting the percent of adults living with HIV (PLWH) on ART. The baseline scenario assumes 95% ART coverage among PLWH by 2028 (4.8% increase per year) based on recent ART scale-up in Viet Nam; test coverage increases by 6.0% per year with annual HIV testing (HIV RDT or dual RDT), and by 7.2% per year with biannual testing. Maximum test coverage is 95% for each model. All models assume ART coverage of 66% of men and 72% of women living with HIV in 2020 based on estimates from the Viet Nam HIV-AIDS Technical Working Group (TWG). We assume universal treatment among those who test positive for syphilis, individuals treated cannot become re-infected within the same year,[17] and no changes to syphilis prevalence under test case scenarios.

Cost-Effectiveness

Health impact was measured in DALYs averted, HIV infections averted, syphilis infections treated, and AIDS-related deaths averted over the 15-year time horizon. This time horizon was chosen because it reflects current HIV program planning in Viet Nam. Costs and health benefits were discounted at 3% annually per standard health economic evaluations. Incremental costs were calculated as costs incurred and averted by the testing strategy. We

utilized WHO guidelines for cost-effectiveness threshold: less than gross domestic product (GDP) per capita is considered cost-effective in Viet Nam (\$2,715 USD in 2019).[18]

Model calibration and sensitivity analyses

Models were calibrated to national HIV prevalence estimates for each key population. Monte Carlo sensitivity analyses were conducted to evaluate robustness of results to changes in: HIV and syphilis testing coverage, scenario program uptake rate, HIV and syphilis testing cost, HIV and syphilis treatment cost, average years on ART, and time horizon. **Table S1** shows the model parameters, ranges, and distributions used in the sensitivity analysis.

Patient and public involvement

It was not appropriate or possible to involve patients or the public in the design, conduct, reporting, or dissemination plans of our research.

Ethics approval

This study did not receive nor require ethics approval as it does not involve human or animal participants.

RESULTS

Increasing annual HIV test coverage from 50% (baseline) to 75% using an HIV RDT (scenario 1) or a dual RDT (scenario 2) is projected to avert 3,206 HIV infections and 660 AIDS-related deaths by 2035 in Viet Nam (**Table 3**). Annual testing using dual RDT led to treatment of an additional 7,719 syphilis cases over 15 years compared to using HIV RDT, but the number of HIV infections averted was the same. HIV testing with either HIV or dual RDT biannually (scenarios 3, 4, & 5) was projected to avert an additional 875 HIV infections and 183 AIDS-related deaths by 2035 compared to annual testing. Testing using a dual HIV/syphilis RDT biannually among key populations is projected to lead to an additional 124,460 syphilis cases treated by 2035, compared to annual testing using a dual RDT (116,680 total syphilis cases treated).

Table 3. Estimated HIV and syphilis infections, and cost-effectiveness of increased HIV and Dual HIV/syphilis testing among key populations in Viet Nam from 2020-2035. Each scenario refers to the number of tests per year. The baseline scenario assumes that 50% of key populations are tested for HIV each year and syphilis testing rates are specific to each sub-population (FSW, MSM, and PWID). Scenarios including one test per year assume a 75% test acceptance rate, and those that include two tests per year assume a 75% test acceptance rate for the first test, and a 68.5% test acceptance rate for the second test. *Incremental cases averted*, *Total DALYs averted*, and *ICERs* compare each scenario to the previous one.

		Scenario					
		Baseline	1 Dual Test	1 HIV Test	1 HIV & 1 Dual	2 HIV Tests	2 Dual Tests
HIV	New HIV infections	57,902	54,696	54,696	53,821	53,821	53,821
	AIDS deaths	13,877	13,217	13,217	13,034	13,034	13,034
	Total HIV DALYs	174,567,240	174,508,007	174,508,007	174,490,608	174,490,608	174,490,608
Syphilis	Total cases treated	108,901	116,680	108,901	116,680	108,901	233,361
	Total DALYs treated	3,466	3,713	3,466	3,713	3,466	7,426
Incremental cases averted	HIV infections averted	-	3,206	0	875	0	0
	HIV DALYs averted	-	59,233	0	17,399	0	0
	Syphilis cases treated	-	7,779	-7,779	7,779	-7,779	124,460
	Syphilis DALYs averted	-	248	-248	248	-248	7,426
Total DALYs averted (HIV & Syphilis)		-	-	59,481	-248	17,647	-248
Costs (USD)	Net Costs	\$34,795,660	\$30,123,774	\$36,853,771	\$47,943,060	\$54,673,057	\$57,292,031
	HIV testing	\$16,491,955	-	\$24,683,204	\$19,677,541	\$44,360,744	-
	HIV treatment averted	-	-\$6,133,138	-\$6,133,138	-\$7,991,393	-\$7,991,393	-\$7,991,393
	Syphilis testing	\$17,740,540	-	\$17,740,540	-	\$17,740,540	-
	Syphilis treatment	\$563,165	\$603,395	\$563,165	\$603,395	\$563,165	\$1,206,793
	Dual testing	-	\$35,653,516	-	\$35,653,516	-	\$64,076,631
Total incremental costs		-	-\$4,671,887	\$6,729,997	\$11,089,289	\$6,729,997	\$2,618,974
ICERs (cost per DALY averted)		-	Cost-saving	<i>Dom</i>	\$1,024	<i>Dom</i>	\$2,518

*DALY=disability adjusted life-years, USD=United States dollars, ICERs=incremental cost-effectiveness ratios, FSW=female sex workers, MSM=men who have sex with men, PWID=people who inject drugs

1
2
3
4 213 The most effective strategy was biannual testing with the dual RDT, which was projected to avert 4,081
5
6 214 HIV infections (7% of total infections), 76,632 HIV DALYs (0.04% of total HIV DALYs), and treat
7
8 215 124,460 cases of syphilis by 2035 compared to the baseline scenario. The discounted cost of implementing
9
10
11 216 this scenario over 30 years is \$57.3 million USD compared to \$34.8 million USD for the baseline scenario.
12
13 217 The testing cost of implementing biannual testing using the dual RDT is almost four times the cost of
14
15 218 baseline testing with an HIV RDT (\$64.1 million vs. \$16.5 million, respectively), but an estimated \$8.0
16
17 219 million USD in HIV treatment costs would be saved by biannual HIV testing, and \$17.7 million USD in
18
19
20 220 syphilis testing costs would be averted by using the dual RDT. The cost of biannual testing with an HIV
21
22 221 RDT and continuing to test for syphilis with RPR is slightly higher than biannual testing with the dual
23
24 222 RDT (\$57.3 vs. \$54.7 million USD, respectively), but the latter strategy treats an estimated 124,000 more
25
26
27 223 cases of syphilis over 15 years.

28
29
30 224 Annual testing with the dual RDT is cost saving compared to the baseline scenario (**Figure 1**). Annual
31
32 225 HIV testing with RDT is more expensive and averts fewer DALYs than with the dual RDT (strongly
33
34 226 dominated). The next most efficient scenario is biannual testing using one dual RDT and one HIV RDT,
35
36 227 which is cost-effective (\$1,024 USD per DALY averted). Biannual testing with the dual RDT is also cost-
37
38
39 228 effective (\$2,518 USD per DALY averted) and more cost-effective than using the HIV RDT (weakly
40
41 229 dominated). Despite slightly higher initial costs, the discounted cost of annual testing with a dual RDT
42
43 230 becomes less than that of current testing within two years, due to decreased ART costs associated with
44
45
46 231 HIV averted (**Figure S1**).

47
48
49 232 Sensitivity analyses including all scenarios found that an annual dual RDT (scenario 2) is cost-saving in
50
51 233 59% of the simulations and either cost-saving or cost-effective (at \$2,715 per DALY averted) in all
52
53 234 simulations (**Table S2**). In non-dominated scenarios (scenarios 2, 3, and 5), using dual RDT annually or
54
55 235 biannually was cost-effective or cost-saving in most simulations, while biannual testing with one dual
56
57
58
59

1
2
3 236 RDT and one HIV RDT was cost-saving in only 31% of simulations (**Figure 2**). In univariate sensitivity
4
5 237 analysis adjusting costs, our scenarios that involve one dual RDT (scenarios 2 and 3) remain cost-effective
6
7
8 238 even after all costs (testing and treatment) are increased by 50%. In this sensitivity analysis, biannual dual
9
10 239 testing is no longer cost-effective (\$3,777 per DALY averted).
11
12

13 240

14

15 241 **DISCUSSION**

16

17

18 242 In our model, we found that implementing annual testing with the dual RDT at 75% coverage was cost-
19
20 243 saving, averted more HIV infections, and treated more syphilis cases compared to annual testing using
21
22
23 244 HIV RDT at 50% coverage and current syphilis testing in Viet Nam. While biannual testing with one dual
24
25 245 RDT and one HIV RDT was projected to be more costly, it would avert more HIV and syphilis related
26
27 246 DALYs and using dual RDT for both tests would avert additional DALYs attributed to syphilis. Increasing
28
29
30 247 the frequency of HIV testing to one or two tests per year using only HIV RDTs, while continuing to test
31
32 248 for syphilis using RPR, was not efficient compared to other strategies.
33

34

35 249 Implementing biannual testing substantially increases testing costs, but also prevents more HIV infections,
36
37 250 therefore averting more ART-related costs. Increasing test frequency may be cost-saving or cost-effective
38
39 251 although it incurs considerable costs in the near term while costs averted may not be observed for many
40
41
42 252 years. Annual testing using a dual RDT can help offset some near-term costs as it is less expensive than
43
44 253 using HIV RDT and syphilis RPR. Policymakers must weigh the health impact and cost-effectiveness of
45
46 254 different testing scenarios over time against current affordability given HIV and syphilis testing budgets;
47
48 255 however, using the dual RDT will help integrate syphilis testing within existing HIV testing programs,
49
50
51 256 improving program efficiencies.[19]

52

53
54 257 Implementation of dual RDT is occurring in some settings; preliminary reports indicate that 48% of
55
56 258 countries use dual RDT in ANC, and 25% use dual RDT in key populations, although the extent of this
57

58

59

60

1
2
3 259 use is unknown (WHO HIV Testing Services, 2021). PEPFAR and the Global Fund cover dual RDT in
4
5
6 260 ANC,[20] and there are multiple dual RDTs qualified by the Global Fund and WHO.[21] The use of dual
7
8 261 RDT during ANC could be a model for improving HIV/STI integration among those at high risk for both
9
10 262 HIV and syphilis, such as key populations, however, there are multiple operational challenges associated
11
12
13 263 with using dual tests, namely that of integrating HIV and STI programs.[22]

14
15 264 Benefits of the dual test are its cost-effectiveness and potential to reach more at-risk individuals. Annual
16
17
18 265 or biannual testing can enable earlier identification of HIV-positive individuals for faster ART initiation
19
20 266 and prevention of onward transmission. Annual HIV testing for key populations is recommended by
21
22 267 WHO, and more frequent testing (every 3-6 months) may be advised for those with individual risk factors,
23
24
25 268 including those using pre-exposure prophylaxis (PrEP) and key populations presenting with STIs.[23]
26
27 269 Individuals presenting with syphilis symptoms should also test for HIV, and using the dual RDT is less
28
29 270 costly as compared to a syphilis RPR and HIV RDT. As policy makers scale up PrEP among key
30
31
32 271 populations in Viet Nam, including at least one dual RDT in the testing algorithm may be more cost-
33
34 272 effective than using HIV RDTs alone. In addition, using dual RDT tests can facilitate lay providers to
35
36 273 offer both HIV and syphilis testing for their community.[24]

37
38
39 274 Our results were robust to sensitivity analyses, suggesting that testing annually or biannually using dual
40
41 275 RDTs remains cost-effective if testing costs increase and HIV prevalence decreases. In scenarios
42
43
44 276 involving dual RDT, the majority (>98%) of benefits, as measured in DALYs, come from averting HIV
45
46 277 infections rather than treating syphilis due to the relatively larger burden of disease from HIV than
47
48 278 syphilis. However, since the cost of a dual RDT is only slightly higher than the cost of an HIV RDT, it is
49
50 279 cheaper to use a dual RDT than separate HIV RDT and syphilis RPR tests.

51
52
53 280 Increased HIV testing can reduce HIV-associated morbidity and mortality and transmission from PLHIV
54
55
56 281 through early detection and initiation of ART. While models suggest high ART coverage would result in

1
2
3 282 substantial declines in HIV incidence,[25, 26] empiric data from countries with population-level viral
4
5 283 suppression exceeding 73% (e.g. Australia, eSwatini, and Thailand) have observed less significant
6
7
8 284 reductions in HIV incidence relative to predictions from mathematical models.[27] Similarly, when high
9
10 285 ART coverage was achieved in a series of cluster-randomized trials in sub-Saharan Africa, it resulted in
11
12 286 decreased population-level HIV incidence; however, this decrease was insufficient to end HIV as a public
13
14
15 287 health threat.[28–31] These discrepancies may be attributed to delayed diagnosis and ART initiation
16
17 288 following infection,[32, 33] and gaps in the 95-95-95 targets for some population groups, for example
18
19 289 young men and key populations. More frequent HIV testing strategies could increase earlier diagnosis and
20
21
22 290 initiation on ART, and focusing testing and linkage efforts on key populations could reduce the access
23
24 291 and coverage disparities in these groups. However, more frequent testing will also increase program costs,
25
26 292 not only through additional commodity procurement, but also for health systems, program coordination,
27
28
29 293 and outreach. In settings of concentrated HIV epidemics, health planners may benefit from targeting
30
31 294 limited testing resources towards high-risk groups such as key populations.
32

33
34 295 Dual RDTs may also increase syphilis testing frequency and coverage among key populations who are
35
36 296 more likely to access HIV testing. Previous research has shown that coupling rapid syphilis testing in
37
38 297 ANC may also increase HIV test coverage in LMICs, particularly in settings where HIV test coverage is
39
40
41 298 low.[34] This strategy may be similarly effective at increasing test coverage for both diseases among key
42
43 299 populations, as well as augment current ANC testing by reaching women in key populations who present
44
45 300 late or are missed by ANC services. While there is a lack of data on dual RDTs among key populations,
46
47 301 models of dual RDT during ANC have been shown to be cost-saving or cost-effective among both key
48
49
50 302 populations and the general population of pregnant women.[7, 35] While dual RDTs are likely more
51
52 303 effective in the context of ANC since testing can avert more adverse outcomes associated with congenital
53
54
55
56
57
58
59

1
2
3 304 syphilis and mother-to-child HIV transmission, we find dual RDTs may also be cost-effective among non-
4
5 305 pregnant key populations.
6
7

8 306 Our results are consistent with previously published models that show expanded testing and early access
9
10
11 307 to ART for key populations in Viet Nam will cost-effectively reduce the country's HIV burden.[36, 37]
12
13 308 Additionally, models from both low- and high-resource countries suggest HIV testing every 3-6 months
14
15 309 among key populations can be cost-effective in concentrated epidemics.[38][39] However, HIV risk
16
17 310 within key populations is not homogenous; further targeting of higher-risk groups within key populations
18
19
20 311 may be needed to achieve efficient testing regimens. While we examine the impact of increased testing
21
22 312 frequency among key populations as a whole, previous research has described the benefits of targeting
23
24 313 high-risk groups within key populations.[40] Individuals who engage in risky behaviors, such as those
25
26
27 314 with more sexual partners, practicing unprotected sex, or needle sharing may benefit from additional
28
29 315 testing or linkage to HIV prevention such as PrEP. Further research is needed on the optimal testing
30
31 316 intervals for higher-risk groups of key populations.
32
33

34 317 Approximately one-third of key populations are not aware of their HIV status. Programs focusing on HIV
35
36 318 testing and treatment among FSW and PWID in Viet Nam have shown success in reducing HIV
37
38
39 319 prevalence; however, less than a third of MSM reported testing for HIV in 2015, likely contributing to
40
41 320 increases in HIV prevalence among MSM in the past decade.[41] Annual syphilis testing among key
42
43 321 populations in Viet Nam is similarly low, ranging from 16% among PWID to 36% among FSW. [14–16]
44
45
46 322 Due to high dual prevalence of HIV and syphilis among key populations, dual testing is a promising
47
48 323 strategy to increase testing coverage and linkage to care.
49

50
51 324 Our analysis has several limitations. We did not include the cost of scaling-up and training providers in
52
53 325 administering dual RDTs. However, RDT are easy to use and can be administered by a lay provider, and
54
55 326 rapid results can minimize loss to follow-up. Overall, dual RDTs have been shown to have adequate
56
57
58
59
60

1
2
3 327 performance in field settings in Viet Nam among key populations.[42] Dual RDTs may also increase HIV
4
5 328 test coverage as they can be easily conducted by community health workers outside of healthcare settings,
6
7
8 329 and they may be more acceptable to some members of key populations who are concerned about stigma
9
10 330 associated with testing.[43] Despite this, some additional training, supervision, and support will be needed
11
12 331 to scale-up dual RDT use among key populations.
13
14

15 332 Some model assumptions regarding the timing of HIV and syphilis testing may be inaccurate. We assumed
16
17 333 in scenarios that included a dual RDT, additional syphilis RPR tests would not be conducted. PLWH who
18
19
20 334 know their status and present for syphilis screening do not need an HIV test. We assume regular testing
21
22 335 intervals for the entire population in each scenario, but it is possible people who engage in risky behaviors
23
24 336 or experience symptoms may seek more frequent retesting than biannually. We did not include the
25
26
27 337 increased costs of outreach to achieve increased test coverage of key populations. Considerable
28
29 338 expansions of first time testing among MSM in Viet Nam have recently been achieved through social
30
31 339 media campaigns, perhaps providing a guide for cost-effectively increasing testing uptake among key
32
33 340 populations.[41, 44] We also did not consider the burden that increasing the testing coverage and
34
35
36 341 frequency may have on the health system; however, as testing may be conducted effectively using lay
37
38 342 providers, increased testing may not substantially impact the provision of other services.[43] Although
39
40
41 343 targeting key populations in lower prevalence regions may be more difficult and costly, these results are
42
43 344 robust to increased costs and it will likely remain an effective use of resources. We assume that syphilis
44
45 345 screening will not impact syphilis prevalence rates. Increased screening may reduce prevalence by
46
47 346 increasing early treatment, but syphilis screening also has the potential to increase prevalence as
48
49
50 347 individuals with latent syphilis are unlikely to transmit the infection to others unless they are treated and
51
52 348 then infected again. Finally, there is limited data on population size, HIV and syphilis prevalence, and
53
54
55
56
57
58
59

1
2
3 349 health seeking behaviors among key populations. We based our model input on estimates included in
4
5
6 350 published literature as well as Viet Nam country sources.
7

8 351 Since data on the impact of retesting on population HIV incidence is limited, we made conservative
9
10
11 352 assumptions about the frequency of linkage to care and ART use following retesting. We assumed that
12
13 353 HIV testing frequency would increase in Viet Nam among key populations in the baseline scenario but
14
15 354 testing frequency would increase more quickly under the other scenarios. Because of this, we believe our
16
17
18 355 estimates of the impact of increased testing frequency are conservative.
19

20 356 Our study suggests that annual or biannual HIV and syphilis testing among key populations in Viet Nam
21
22
23 357 using a dual RDT will increase HIV and syphilis detection and treatment, while remaining cost-saving or
24
25 358 cost-effective. Integrating HIV and other STI testing can streamline services as well as expand testing and
26
27 359 help countries with epidemics concentrated in key populations reach 95-95-95 targets.
28
29

30 360

31

32 361 **COMPETING INTERESTS**

33

34
35 362 The authors declare no competing interests.
36

37 363 **FUNDING SOURCE**

38

39 364 WHO-USAID: GHA-G-00-09-00003; NIH/NIAID: K01 AI116298
40

41 42 365 **CONTRIBUTORSHIP STATEMENT**

43

44 366 CJ and AD devised the project and the main conceptual ideas. DC, DG, and RB parameterized the model.
45
46 367 DC and DG carried out the model implementation. VH and SVH provided model feedback. All authors
47
48 368 provided critical feedback and helped shape the research, analysis, and manuscript.
49

50 51 369 **DATA SHARING STATEMENT**

52

53 370 Extra data is available by emailing David Coomes, dcoomes@uw.edu
54
55
56
57
58
59
60

References

- 1
2
3 371
4
5 372 [1] UNAIDS Joint United Nations Programme on HIV/AIDS. *Global AIDS update 2019 - Communities*
6 *at the centre*. Geneva, <https://www.unaids.org/en/resources/documents/2019/2019-global->
7 373 <https://www.unaids.org/en/resources/documents/2019/2019-global->
8 AIDS-update (2019).
9 374
10
11 375 [2] UNAIDS Joint United Nations Programme on HIV/AIDS. *Global AIDS Update 2020: Seizing the*
12 *moment*. Geneva, <https://www.unaids.org/en/resources/documents/2020/global-aids-report>
13 376 <https://www.unaids.org/en/resources/documents/2020/global-aids-report>
14 (2020).
15 377
16
17 378 [3] Cameron CE. Syphilis Vaccine Development: Requirements, Challenges, and Opportunities. *Sex*
18 *Transm Dis* 2018; 45: S17.
19 379
20
21 380 [4] Tsuboi M, Evans J, Davies E, et al. Prevalence of syphilis among men who have sex with men: A
22 380 global systematic review and meta-analysis from 2000 to 2020. *Lancet Glob Heal*; In press.
23 381
24 381
25
26 382 [5] World Health Organization. *Consolidated guidelines on HIV testing services*. Geneva,
27 <https://www.ncbi.nlm.nih.gov/books/NBK316021/> (2015).
28 383
29
30 384 [6] World Health Organization. *WHO Guideline on Syphilis screening and treatment for pregnant*
31 *women*, [https://www.who.int/reproductivehealth/publications/rtis/syphilis-ANC-](https://www.who.int/reproductivehealth/publications/rtis/syphilis-ANC-screenandtreat-guidelines/en/)
32 385 [https://www.who.int/reproductivehealth/publications/rtis/syphilis-ANC-](https://www.who.int/reproductivehealth/publications/rtis/syphilis-ANC-screenandtreat-guidelines/en/)
33 screenandtreat-guidelines/en/ (2017).
34 386
35
36 387 [7] Rodriguez P, Roberts DA, Meisner J, et al. Cost-effectiveness of dual maternal HIV and syphilis
37 387 testing strategies in high and low HIV prevalence countries: a modeling study. *Lancet Glob Heal*
38 388 2021; 9: E61–E71.
39 389
40 389
41
42 390 [8] World Health Organization. *Consolidated Guidelines on the Use of Antiretroviral Drugs for*
43 390 *Treating and Preventing HIV Infection*. 2016. Epub ahead of print 2016. DOI:
44 391 10.1017/CBO9781107415324.004.
45 391
46 392
47
48 393 [9] UNAIDS. *90-90-90 An ambitious treatment target to help end the AIDS epidemic*,
49 393 <https://www.unaids.org/en/resources/909090> (2016).
50 394
51 394
52
53 395 [10] Hakim AJ, MacDonald V, Hladik W, et al. Gaps and opportunities: measuring the key population
54 395 cascade through surveys and services to guide the HIV response. *J Int AIDS Soc* 2018; 21:
55 396
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

397 e25119.

- [11] World Health Organization. *Global Health Sector Strategy on Sexually Transmitted Infections 2016-2021*, <https://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/> (2016).
- [12] World Health Organization. Global Health Observatory data repository: Data on syphilis, <https://apps.who.int/gho/data/node.main.A1357STI?lang=en> (accessed 4 June 2020).
- [13] Stover J, Brown T, Puckett R, et al. Updates to the Spectrum/Estimations and Projections Package model for estimating trends and current values for key HIV indicators. *AIDS* 2017; 31: S5–S11.
- [14] Justumus P, Colby D, Mai Doan Anh T, et al. Willingness to use the Internet to seek information on HIV prevention and care among men who have sex with men in Ho Chi Minh City, Vietnam. *PLoS One* 2013; 8: e71471.
- [15] Nguyen TA, Hoang LT, Pham VQ, et al. Risk factors for HIV-1 seropositivity in drug users under 30 years old in Haiphong, Vietnam. *Addiction* 2001; 96: 405–413.
- [16] Ngo AD, Ratliff EA, Mccurdy SA, et al. Health-seeking behaviour for sexually transmitted infections and HIV testing among female sex workers in Vietnam. *AIDS Care - Psychol Socio-Medical Asp AIDS/HIV* 2007; 19: 878–887.
- [17] Feldman J, Mishra S. What could re-infection tell us about R0? A modeling case-study of syphilis transmission. *Infect Dis Model* 2019; 4: 257–264.
- [18] World Bank. World Bank Data: GDP per capita (current US\$) - Vietnam, <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=VN> (accessed 16 December 2020).
- [19] Ong JJ, Fu H, Smith MK, et al. Expanding syphilis testing: a scoping review of syphilis testing interventions among key populations. *Expert Rev Anti Infect Ther* 2018; 16: 423–432.
- [20] U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). *PEPFAR 2021 Country and Regional Operational Plan (COP/ROP) Guidance for all PEPFAR Countries*, <https://www.state.gov/wp-content/uploads/2020/12/PEPFAR-COP21-Guidance-Final.pdf> (2021).

- 1
2
3 423 [21] The Global Fund. *List of HIV Diagnostic test kits and equipments classified according to the*
4 *Global Fund Quality Assurance Policy*,
5 424 *https://www.theglobalfund.org/media/5878/psm_productshiv-who_list_en.pdf* (2021).
6
7 425
8
9 426 [22] Broyles LN, Boeras D, Peeling RW. Implementation of dual maternal HIV-Syphilis testing: The
10 *devil is in the details. Lancet Glob Heal* 2021; 9: e595.
11 427
12
13 428 [23] World Health Organization. *Consolidated guidelines on HIV testing services*. Geneva,
14 *https://www.who.int/publications/i/item/978-92-4-155058-1* (2019).
15 429
16
17
18 430 [24] Nguyen V, Anh L, Thong N, et al. High prevalence of HIV, syphilis and HCV among key
19 *populations and partners: results from an integrated multiple diseases testing led by community*
20 *in Viet Nam. In: Poster exhibition IAS 2019. Mexico City, Mexico, 2019.*
21
22 432
23
24 433 [25] Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral
25 *therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet* 2009;
26 434 *373: 48–57.*
27
28 435
29
30 436 [26] Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: Systematic comparison of
31 *mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South*
32 437 *Africa. PLoS Med*; 9. Epub ahead of print July 2012. DOI: 10.1371/journal.pmed.1001245.
33
34 438
35
36 439 [27] UNAIDS. AIDSinfo | UNAIDS, *https://aidsinfo.unaids.org/* (accessed 27 May 2020).
37
38
39 440 [28] Iwuji CC, Orne-Gliemann J, Larmarange J, et al. Universal test and treat and the HIV epidemic in
40 *rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV* 2018;
41 441 *5: e116–e125.*
42
43 442
44
45 443 [29] Makhema J, Wirth KE, Pretorius Holme M, et al. Universal Testing, Expanded Treatment, and
46 *Incidence of HIV Infection in Botswana. N Engl J Med* 2019; 381: 230–242.
47 444
48
49 445 [30] Havlir D V., Balzer LB, Charlebois ED, et al. HIV Testing and Treatment with the Use of a
50 *Community Health Approach in Rural Africa. N Engl J Med* 2019; 381: 219–229.
51 446
52
53 447 [31] Hayes RJ, Donnell D, Floyd S, et al. Effect of Universal Testing and Treatment on HIV Incidence —
54 *HPTN 071 (PopART). N Engl J Med* 2019; 381: 207–218.
55 448
56
57
58
59
60

- 1
2
3 449 [32] Akullian A, Bershteyn A, Jewell B, et al. The missing 27%. *AIDS* 2017; 31: 2427–2429.
4
5
6 450 [33] Abdool Karim SS. HIV-1 Epidemic Control — Insights from Test-and-Treat Trials. *N Engl J Med*
7
8 451 2019; 381: 286–288.
9
10 452 [34] Swartzendruber A, Steiner RJ, Adler MR, et al. Introduction of rapid syphilis testing in antenatal
11
12 453 care: A systematic review of the impact on HIV and syphilis testing uptake and coverage. *Int J*
13
14 454 *Gynecol Obstet* 2015; 130: S15–S21.
15
16 455 [35] Gliddon HD, Peeling RW, Kamb ML, et al. A systematic review and meta-analysis of studies
17
18 456 evaluating the performance and operational characteristics of dual point-of-care tests for HIV
19
20 457 and syphilis. *Sex Transm Infect* 2017; 93: S3–S15.
21
22 458 [36] Kato M, Long NH, Duong BD, et al. Enhancing the Benefits of Antiretroviral Therapy in Vietnam:
23
24 459 Towards Ending AIDS. *Curr HIV/AIDS Rep* 2014; 11: 487–495.
25
26
27 460 [37] Kato M, Granich R, Bui DD, et al. The potential impact of expanding antiretroviral therapy and
28
29 461 combination prevention in Vietnam: Towards elimination of HIV transmission. *J Acquir Immune*
30
31 462 *Defic Syndr*. Epub ahead of print 2013. DOI: 10.1097/QAI.0b013e31829b535b.
32
33 463 [38] Kazemian P, Costantini S, Kumarasamy N, et al. The Cost-effectiveness of Human
34
35 464 Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk
36
37 465 Groups in India. *Clin Infect Dis* 2020; 70: 633–642.
38
39 466 [39] Cipriano LE, Zaric GS, Holodniy M, et al. Cost Effectiveness of Screening Strategies for Early
40
41 467 Identification of HIV and HCV Infection in Injection Drug Users. *PLoS One*. Epub ahead of print
42
43 468 2012. DOI: 10.1371/journal.pone.0045176.
44
45 469 [40] Reitsema M, Steffers L, Visser M, et al. Cost-Effectiveness of Increased HIV Testing among MSM
46
47 470 in The Netherlands. *AIDS* 2019; 33: 1807–1817.
48
49
50 471 [41] Green KE, Vu BN, Phan HT, et al. From conventional to disruptive: upturning the HIV testing
51
52 472 status quo among men who have sex with men in Vietnam. *J Int AIDS Soc* 2018; 21: e25127.
53
54 473 [42] Withers K, Bristow C, Nguyen M, et al. A field evaluation of a rapid dual immunoassay for human
55
56 474 immunodeficiency virus and syphilis antibodies, Hanoi, Vietnam. *Int J STD AIDS* 2019; 30: 173–
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

475 180.


- [43] Vu BN, Green KE, Phan HTT, et al. Lay provider HIV testing: A promising strategy to reach the undiagnosed key populations in Vietnam. *PLoS One* 2018; 13: e0210063.
- [44] Nguyen VTT, Phan HTT, Kato M, et al. Community-led HIV testing services including HIV self-testing and assisted partner notification services in Vietnam: lessons from a pilot study in a concentrated epidemic setting. *J Int AIDS Soc* 2019; 22: e25301.
- [45] Clatts MC, Goldsamt LA, Giang LM, et al. Sexually transmissible infection and HIV prevention and treatment for young male sex workers in Vietnam: Findings from the SHEATH intervention. *Sex Health*. Epub ahead of print 2016. DOI: 10.1071/SH16051.
- [46] Bao A, Colby DJ, Trang T, et al. Correlates of HIV Testing Among Transgender Women in Ho Chi Minh, Vietnam. *AIDS Behav*. Epub ahead of print 2016. DOI: 10.1007/s10461-016-1574-8.
- [47] Magnani R, Riono P, Nurhayati, et al. Sexual risk behaviours, HIV and other sexually transmitted infections among female sex workers in Indonesia. *Sex Transm Infect*. Epub ahead of print 2010. DOI: 10.1136/sti.2009.038059.
- [48] Cassini A, Colzani E, Pini A, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): Results from the burden of communicable diseases in Europe study, European Union and European economic countries, 2009 to 2013. *Eurosurveillance*. Epub ahead of print 2018. DOI: 10.2807/1560-7917.ES.2018.23.16.17-00454.

1
2
3 494 **FIGURE LEGENDS**
4


5 495 **Figure 1. Efficiency frontier presenting the total disability adjusted life years (DALYs) and costs for**
6 496 **five testing scenarios among key populations.** The solid line indicates the scenarios that are not
7 497 dominated by other scenarios. Dominated indicates that a scenario is either more costly and less effective
8 498 or has a higher ICER than a scenario that is more effective. The ICERs for the non-dominated scenarios
9 499 are shown. DALYs=disability adjusted life-years, ICER=incremental cost-effectiveness ratio, RDT=rapid
10 500 diagnostic test, USD=United States dollars
11

12 501
13
14 502
15
16 503
17 504 **Figure 2. Sensitivity analysis of non-dominated scenarios using a Monte Carlo simulation of the**
18 505 **cost effectiveness of HIV/syphilis dual testing among key populations in Viet Nam.** Plot shows 10,000
19 506 iterations in which 17 key parameters were randomly adjusted. All points below the green line are cost-
20 507 effective at \$2,715 per DALY averted and those below the solid black line (y-intercept) are cost-saving.
21 508 Only non-dominated scenarios are shown in this figure; cost-effectiveness of *1 Dual Test* is compared to
22 509 baseline, *1 HIV Test & 1 Dual Test* is compared to *1 Dual Test*, and *2 Dual Tests* is compared to *1 HIV*
23 510 *Test & 1 Dual Test*. DALYs=disability adjusted life-years, ICER=incremental cost-effectiveness ratio,
24 511 RDT=rapid diagnostic test, USD=United States dollars.
25
26
27 512
28
29 513
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



2116x1058mm (72 x 72 DPI)



2116x1058mm (72 x 72 DPI)

Table S1. Parameters and probability distributions for Monte Carlo simulation. Table shows the baseline model parameter values and the probability distributions used for random draws of 17 variables for 10,000 Monte Carlo simulations. Beta distributions were used for all proportion parameters. For the beta distribution, the alpha and beta parameters were calculated as the baseline value multiplied by 100, except for the *impact* parameter where an alpha and beta of 25 was used. Gamma distributions were used for all other parameters. For the gamma distribution, the alpha parameter was calculated as the square of the baseline parameter divided by the square of the standard deviation. The beta parameter was calculated as the square of the standard deviation divided by the baseline parameter.


Model Parameter	Baseline value	Distribution	St. Dev	alpha/beta
Baseline HIV test acceptance	50%	Beta	N/A	50
Recommended test acceptance	75%	Beta	N/A	75
Additional test drop off rate	10%	Beta	N/A	10
HIV Lay Test Cost	\$4.50	Gamma	\$3.00	N/A
Syphilis RPR1 Cost	\$6.28	Gamma	\$3.50	N/A
HIV/Syphilis Dual Test Cost	\$6.50	Gamma	\$3.50	N/A
ART Treatment Cost	\$285	Gamma	\$50	N/A
Syphilis Treatment Cost	\$6.50	Gamma	\$3.50	N/A
Avg Years on ART	25	Gamma	3	N/A
Time Horizon	2035	Gamma	3	N/A
Impact	100%	Beta	N/A	25
Baseline Syphilis test acceptance FSW	35%	Beta	N/A	35
Baseline syphilis test acceptance MSM	27%	Beta	N/A	27
Baseline syphilis test acceptance PWID	16%	Beta	N/A	16
Baseline syphilis prevalence FSW	2.1%	Beta	N/A	2.1
Baseline syphilis prevalence MSM	6.7%	Beta	N/A	6.7
Baseline syphilis prevalence PWID	0.3%	Beta	N/A	0.3

Table S2. Sensitivity analysis of all scenarios using a Monte Carlo simulation. Table shows the percentage of simulations (10,000 iterations) in which each scenario is cost-effective (at \$500 or \$2,715 per DALY averted), cost-saving, or less-effective. Less effective scenarios are both less effective and more costly as compared to the scenario above. Scenarios are arranged in order of increasing cost and each scenario is compared to the one immediately above; 1 Dual HIV/syphilis RDT is compared to the baseline scenario.

Scenario	Cost-effective	Cost-effective	Cost-saving	Less effective
	(\$500)	(\$2,715)		
1 Dual HIV/syphilis RDT	87%	100%	59%	0%
1 HIV RDT	11%	12%	11%	69%
1 Dual HIV/syphilis RDT & 1 HIV RDT	45%	87%	31%	0%
2 HIV RDTs	11%	12%	11%	69%
2 Dual HIV/syphilis RDTs	49%	55%	48%	0%

DALY=disability adjusted life-year, RDT=rapid diagnostic test

Figure S1. Cost pressure analysis of testing scenarios. Figure shows the discounted cost over time of each scenario. Costs are discounted 3% with a time horizon from 2020 – 2035. Baseline costs include testing costs assuming that 50% of key populations are tested for HIV each year and syphilis testing rates are specific to each sub-population (FSW, MSM, and PWID), and syphilis treatment costs. All other scenarios include the cost of HIV treatment averted compared to the baseline scenario, testing costs, and syphilis treatment costs. Scenarios including one test per year assume a 75% test acceptance rate, and those that include two tests per year assume a 75% test acceptance rate for the first test, and a 68.5% test acceptance rate for the second test. Each scenario refers to the number of tests per year. RDT=rapid diagnostic test, USD=United States dollars



BMJ Open

Cost-effectiveness of implementing HIV and HIV/syphilis dual testing among key populations in Viet Nam: a modeling analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-056887.R1
Article Type:	Original research
Date Submitted by the Author:	08-Jun-2022
Complete List of Authors:	Coomes, David; University of Washington, Department of Epidemiology; University of Washington, Department of Global Health Green, Dylan; University of Washington, Department of Epidemiology; University of Washington, Department of Global Health Barnabas, Ruanne; University of Washington, Department of Global Health; University of Washington, Department of Medicine Sharma , Monisha; University of Washington, Department of Global Health Barr-DiChiara, Magdalena; World Health Organization, Department of Global HIV, Hepatitis and STI Programmes Jamil, Muhammad; World Health Organization, Department of Global HIV, Hepatitis and STI Programmes Baggaley, R; World Health Organization, Department of Global HIV, Hepatitis and STI Programmes Owiredu, Morkor Newman; World Health Organization, Department of Global HIV, Hepatitis and STI Programmes Macdonald, Virginia; World Health Organization, Department of Global HIV, Hepatitis and STI Programmes Nguyen, Van Thi Thuy; World Health Organization, Viet Nam Country Office Vo, Son; Government of Viet Nam Ministry of Health, Viet Nam Authority for HIV/AIDS Prevention and Control Taylor, Melanie; World Health Organization, Department of Global HIV, Hepatitis and STI Programmes; Centers for Disease Control and Prevention, Division of STD Prevention Wi, Teodora; World Health Organization, Department of Global HIV, Hepatitis and STI Programmes Johnson, Cheryl; World Health Organization, Department of Global HIV, Hepatitis and STI Programmes; London School of Hygiene & Tropical Medicine, Clinical Research Department Drake, Alison L.; University of Washington, Department of Global Health; University of Washington, Department of Epidemiology
Primary Subject Heading:	Health economics
Secondary Subject Heading:	Epidemiology, Global health, HIV/AIDS, Health policy
Keywords:	HEALTH ECONOMICS, HIV & AIDS < INFECTIOUS DISEASES, PUBLIC HEALTH

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Cost-effectiveness of implementing HIV and HIV/syphilis dual testing among key populations in Viet Nam: a**
2
3 **modeling analysis**

4
5 David Coomes^{1,2}, Dylan Green^{1,2}, Ruanne Barnabas^{1,2,3}, Monisha Sharma², Magdalena Barr-DiChiara⁴,
6 Muhammad S. Jamil⁴, Rachel Baggaley⁴, Morkor Newman Owiredo⁴, Virginia Macdonald⁴, Van Nguyen⁵, Son
7 Vo Hai⁶, Melanie M. Taylor^{4,7}, Teodora E Wi⁴, Cheryl Johnson^{4,8}, Alison L. Drake^{1,2§}
8

9
10 1. University of Washington, Department of Epidemiology, Seattle, WA, USA

11 2. University of Washington, Department of Global Health, Seattle, WA, USA

12 3. University of Washington, Department of Medicine, Seattle, WA, USA

13 4. Department of Global HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland

14 5. Viet Nam Country Office, World Health Organization, Hanoi, Viet Nam

15 6. Viet Nam Authority for HIV/AIDS Prevention and Control, Ministry of Health, Hanoi, Viet Nam

16 7. Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA

17 8. Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom

18
19 § Corresponding author: Alison L. Drake

20 325 9th Avenue

21 Box 359909

22 Seattle, WA 98195, USA

23 Phone: 1-206-543-5847

24 Email: adrake2@uw.edu

25
26 Disclaimer: The views expressed in this manuscript are those of the authors and do not necessarily represent the
27 official position of the World Health Organization or the United States Centers for Disease Control
28
29

30
31
32
33
34
35
36
37
38
39
40
41
42
43 Word count: 4,323

44
45 Abstract word count: 292

46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Keywords: HIV testing, syphilis testing, key populations, 95-95-95

35 ABSTRACT

36 Objectives

37 Key populations, including sex workers, men who have sex with men, and people who inject drugs, have a high
38 risk of HIV and sexually transmitted infections (STIs). We assessed the health and economic impacts of
39 different HIV and syphilis testing strategies among three key populations in Viet Nam using a dual HIV/syphilis
40 rapid diagnostic test (RDT).

41 Setting

42 We used the Spectrum AIDS Impact Model to simulate the HIV epidemic in Viet Nam and evaluated five
43 testing scenarios among key populations. We used a 15-year time horizon and a provider perspective for costs.

44 Participants

45 We simulate the entire population of Viet Nam in the model.

46 Interventions

47 We modeled five testing scenarios among key populations: 1) annual testing with an HIV rapid diagnostic test
48 (RDT), 2) annual testing with a dual RDT, 3) biannual testing using dual RDT and HIV RDT, 4) biannual
49 testing using HIV RDT, and 5) biannual testing using dual RDT.

50 Primary and secondary outcome measures

51 The primary outcome is incremental cost-effectiveness ratios (ICERS). Secondary outcomes include HIV and
52 syphilis cases.

53 Results

54 Annual testing using a dual HIV/syphilis RDT was cost-effective (\$10 per disability-adjusted life year (DALY))
55 and averted 3,206 HIV cases and treated 27,727 syphilis cases compared to baseline over 15 years. Biannual
56 testing using one dual test and one HIV RDT (\$1,166 per DALY), or two dual tests (\$5,672 per DALY) both
57 averted an additional 875 HIV cases, although only the former scenario was cost-effective. Annual or biannual
58 HIV testing using HIV RDTs and separate syphilis tests were more costly and less effective than using one or
59 two dual RDTs.

60 Conclusions

61 Annual HIV and syphilis testing using dual RDT among key populations is cost-effective in Vietnam and
1
2
32 similar settings to reach global reduction goals for HIV and syphilis.
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STRENGTHS AND LIMITATIONS OF THIS STUDY

- Strength: Our model parameters are informed by empiric data including demographic, behavioral, and biological data from government sources, surveys, surveillance, publicly available reports, databases, and peer-reviewed literature.
- Strength: We assess the impact of five testing scale up scenarios using both HIV RDT and dual HIV/syphilis RDT and conduct sensitivity analyses to evaluate uncertainty in model results.
- Limitation: Due to limited data, we make assumptions regarding the timing and uptake of HIV and syphilis testing among key populations that may be inaccurate.
- Limitation: Our model conservatively assumes that increased syphilis testing and treatment will not impact syphilis prevalence, which is currently unknown.

INTRODUCTION

Key populations, including people who inject drugs (PWID), men who have sex with men (MSM), sex workers (SW), and transgender populations are at higher risk of acquiring both HIV and syphilis. HIV incidence is significantly higher among key populations compared to the general population in all geographic regions; however, differences vary substantially by region and by key population.[1] While key populations and their sexual partners represent approximately 25% of new HIV cases in sub-Saharan Africa, they represent 80% of new HIV cases in the rest of the world.[2] Recent data suggests syphilis incidence, while generally remaining stable in low- and middle-income countries (LMIC), is increasing among key populations, particularly MSM.[1, 3, 4] World Health Organization (WHO) HIV testing guidelines recommend HIV retesting at least annually for key populations and more frequent testing (3-6 months) for those with high ongoing risk.[5] WHO guidelines for syphilis screening depend on population and setting. Laboratory-based syphilis testing remains common, however rapid diagnostic tests (RDTs) for syphilis are increasingly available and may be used to improve access to testing and treatment, including among key populations who are disproportionately affected by both HIV and syphilis.[6] With the introduction of prequalified dual HIV/syphilis RDTs, and the recent WHO recommendation to offer dual HIV/syphilis testing in antenatal care (ANC) settings,[7] it is important to evaluate how further integration and expansion of dual HIV/syphilis testing could benefit key populations.

Since 2015, WHO has recommended immediate initiation of antiretroviral therapy (ART) for all people living with HIV (PLHIV) [8] and the United Nations 95-95-95 targets aim to diagnose 95% of PLHIV, provide 95% of PLHIV who know their status with ART, and ensure 95% PLHIV on ART are virally suppressed.[9] Despite progress towards these goals – in 2019 81% of PLHIV knew their HIV status and 67% were on ART – this progress is uneven; only 2/3 of key populations are aware of their HIV status.[2] While key populations lag behind the general population in all phases of testing, linkage to treatment, and viral suppression, the largest gap exists in testing.[10] WHO has also developed a global strategy on sexually transmitted infections (STIs) which aims for a 90% reduction in syphilis incidence by 2030, and 70% of key populations to have access to STI and HIV services, including prevention, testing, and treatment.[11] Increased syphilis testing and treatment may reduce

100 syphilis burden among key and general populations, as well as HIV incidence since early symptomatic syphilis
101 increases risks of HIV acquisition and transmission.[3] Currently, WHO recommends syphilis testing for pregnant
102 women and key populations, however, the optimal frequency of syphilis testing is unknown and recommendations
103 on syphilis testing for other populations are not available.

104 In Viet Nam, the national HIV prevalence is <1% in the general population, and significantly higher in key
105 populations, with prevalence ranging between 3-13% among PWID, MSM, and female sex workers (FSW).
106 Similarly, syphilis prevalence among MSM (6.7%) and FSW (2.1%) are also higher than that of the general
107 population (0.3%).[12] With budgetary constraints in HIV/STI programs and the health sector, identifying cost-
108 effective strategies for targeted HIV and syphilis testing among key groups in Viet Nam is crucial to inform
109 policymakers seeking to optimize resource allocation to maximize population health. We modeled the health
110 impacts and costs associated with varying frequencies of HIV and syphilis testing for key populations, using test
111 scenarios that include a dual HIV/syphilis RDT.

112 **METHODS**

113 **Model**

114 We used the AIDS Impact Model within the Spectrum software package (v 5.76) to simulate the HIV epidemic
115 in Viet Nam from 2020-2035. The model estimates annual HIV incidence, AIDS mortality, and disability. We
116 simulated the impact of increasing HIV testing frequency among key populations using the Goals model within
117 Spectrum, as previously described.[13] Briefly, Spectrum is a deterministic, compartmental mathematical model
118 of HIV transmission stratified by sex and age. Transmission is simulated through male-female and male-male sex
119 acts, needle sharing for injection, and maternal-to-child transmission with specific transmission probabilities for
120 each route. One can further specify parameters for low- and medium-risk groups, as well as high-risk categories
121 including FSW, MSM, and PWID.¹ Each of these high-risk categories is nested within their parent categories and
122

123 ¹ Low-risk heterosexuals are those in stable couples while medium-risk heterosexuals are those that engage in casual sex but are not
124 in a high-risk group (high risk groups: MSM, FSW, PWID).

interact with one another. For example, among MSM, a proportion is assumed to also have female sexual partners. These high-risk categories can be parameterized to have differential rates of partnership and uptake of interventions. The model was parameterized with demographic, behavioral, and biological data from government sources, surveys, surveillance, publicly available reports, databases, and peer-reviewed literature. To estimate syphilis burden, we used key population size estimates from the Goals model and population-specific estimates of prevalence;^[12] we estimate the number of persons in key populations testing positive and treated for syphilis infection under each scenario. This model assumes that syphilis testing and treatment does not impact syphilis prevalence, although increased screening could potentially result in reduced, unchanged, or increased syphilis prevalence depending on coverage.^[14, 15] For both HIV and syphilis, disability-adjusted life years (DALYs) are calculated for each scenario. Model key parameters are shown in **Table 1**.

Settings and Populations

We modeled three key populations: MSM, PWID, and FSW (and their clients) within the HIV epidemic in Viet Nam, using national level HIV prevalence and syphilis prevalence estimates for each key population (**Table 1**).

Table 1. Model parameters for Spectrum input and cost-effectiveness analysis of HIV and syphilis testing scale up among key populations in Viet Nam. ^a = 2018 Viet Nam HIV Sentinel Surveillance. ^b = 2019 Viet Nam HIV Sentinel Surveillance. * = Spectrum model prior. ** = assumed. *** = Based on information from in-country source.

Model parameter	Value
HIV Prevalence	
MSM (incl. TGW) ^a	10.8%
PWID ^b	12.7%
FSW ^a	3.6%
Syphilis Prevalence ^[12]	
MSM (incl. TGW)	6.7%
PWID	0.3%
FSW	2.1%
Baseline syphilis test acceptance	
MSM (incl. TGW) ^{[16],[17],[18]}	27%
PWID ^[19]	16%
FSW ^{[20],[21]}	35%
Syphilis DALYs averted ^[22]	
DALYs averted per syphilis case treated	0.04
ART	

2019 Coverage***	70%
Annual Scale-Up**	4.8%
Transmission Reduction Efficacy*	70%
Mortality Reduction Efficacy*	80%
<hr/>	
Other Prevention	
Condom Use**	50%
Condom Efficacy*	80%
PrEP Coverage (MSM incl. TGW)**	5%
PrEP Efficacy*	90%
PrEP Adherence*	80%
<hr/>	
Costs***	
HIV Lay Test†	\$4.50
Syphilis RPR†	\$6.28
Syphilis TPHA†	\$10.26
HIV/Syphilis Dual Test†	\$6.50
ART‡	\$285
Syphilis Treatment	\$6.50
Time Horizon	2020 - 2035
Discount Rate	3%

† Testing costs include labor, incentives, travel costs, and test kits. Primary cost driver between tests is the cost of the test kit.

‡ ART cost includes labor, laboratory monitoring costs, ARVs, and other recurring costs.

* MSM=men who have sex with men, FSW=female sex workers, PWID=people who inject drugs, TGW=transgender women, ART=antiretroviral therapy, PrEP=pre-exposure prophylaxis, syphilis RPR=syphilis rapid plasma reagin, syphilis TPHA=treponema pallidum hemagglutination assay, DALY=disability-adjusted life year

Scenarios

Our baseline scenario estimates annual HIV testing based on current WHO recommendations and estimated HIV testing rates among key populations,[5] and syphilis testing based on observed uptake. In the baseline scenario, we assume 50% of individuals in key populations test annually for HIV, and syphilis screening with a non-treponemal test (RPR) occurs at rates specific to each key population (**Table 2**).[18–20] Individuals who test positive using RPR are given a confirmatory treponemal (TPHA) test. We modeled HIV RDTs as WHO recommend, limiting the use of lab-based testing such as western blot, especially in hard-to-reach populations, to increase access and limit the loss to follow up.[23] We considered alternative scenarios with varying testing frequency and test type (separate HIV and syphilis RPR, or a combined dual syphilis/HIV RDT) among key populations from 2020 to 2035. Scenarios modeled include: **1**) annual HIV testing with RDT and baseline syphilis RPR testing, **2**) annual testing with dual RDT, **3**) biannual testing (2 times per year), first with dual RDT and then with HIV RDT, **4**) biannual HIV testing with RDT and baseline syphilis RPR testing, and **5**) biannual testing with

dual RDT (**Table 2**). We assumed 75% test acceptance for the first test in all scenarios except baseline, and 90% of those who accepted the first test would accept the second test in all scenarios that include biannual testing. All individuals who test positive for syphilis using the dual test are then tested using RPR and TPHA per current Viet Nam country guidelines.

Table 2: HIV/syphilis testing scenarios among key populations in Viet Nam. The table cells show the proportion of key populations in Viet Nam that receive each test per year. If not specified, the proportion refers to all key populations.

Scenario	Proportion of key population receiving HIV or syphilis testing per year			
	1 HIV test	2 HIV tests	1 syphilis test	2 syphilis tests
Baseline	50%	-	35% (FSW), 27% (MSM), 16% (PWID)	-
1. One HIV RDT	75%	-	35% (FSW), 27% (MSM), 16% (PWID)	-
2. One Dual HIV/syphilis RDT	75%	-	75%	-
3. One HIV RDT & One Dual HIV/syphilis RDT	75%	68%	75%	-
4. Two HIV RDTs	75%	68%	35% (FSW), 27% (MSM), 16% (PWID)	-
5. Two Dual HIV/syphilis RDT	75%	68%	75%	68%

* MSM=men who have sex with men, FSW=female sex workers, PWID=people who inject drugs, RDT=rapid diagnostic test.

We modeled increases in testing coverage by adjusting the percent of people living with HIV (PLWH) on ART; in scenarios with increased testing there is a higher probability that an individual in the model will initiate ART throughout the year. The baseline scenario assumes 95% ART coverage among PLWH by 2028 (4.8% increase per year) based on recent ART scale-up in Viet Nam; test coverage increases by 6.0% per year with annual HIV testing (HIV RDT or dual RDT), and by 7.2% per year with biannual testing. Maximum test coverage is 95% for each model. All models assume ART coverage of 66% of men and 72% of women living with HIV in 2020 based on estimates from the Viet Nam HIV-AIDS Technical Working Group (TWG). Modeled HIV incidence per year is shown in **Figure S1**. We assume universal treatment among those who test positive for syphilis, individuals

175 treated cannot become re-infected within the same year,[24] and no changes to syphilis prevalence under test case
176 scenarios.

177 **Costs**

178 Testing cost inputs include cost per HIV RDT test, rapid plasma reagin (RPR), treponema pallidum
179 hemagglutination (TPHA), and dual HIV/syphilis RDT. We used local data on the personnel, commodities, and
180 transport costs associated with lay testing and estimate costs (**Table 1**). ART costs include personnel,
181 commodities, clinical follow-up, and laboratory monitoring. This analysis includes the costs of intervention
182 delivery and treatment (Benzathine penicillin G and ART) but does not consider additional averted sequelae costs
183 such as the treatment of opportunistic infections due to uncontrolled HIV. All costs are from the provider's
184 perspective and reported in 2019 US dollars.

185 **Cost-Effectiveness**

186 Health impact was measured in DALYs averted, HIV infections averted, syphilis infections treated, and AIDS-
187 related deaths averted over the 15-year time horizon. This time horizon was chosen because it reflects current
188 HIV program planning in Viet Nam. HIV outcomes are modeled for the entire population of Viet Nam while
189 syphilis outcomes are specific to key populations. Costs and health benefits were discounted at 3% annually per
190 standard health economic evaluations.[25] Incremental costs were calculated as costs incurred and averted by the
191 testing strategy. We utilized WHO guidelines for cost-effectiveness threshold: less than gross domestic product
192 (GDP) per capita is considered cost-effective in Viet Nam (\$2,715 USD in 2019).[26]

193 **Model calibration and sensitivity analyses**

194 Models were calibrated to national HIV prevalence data for each key population. Monte Carlo sensitivity analyses
195 were conducted to evaluate robustness of results to changes in: HIV and syphilis testing coverage, scenario
196 program uptake rate, HIV and syphilis testing cost, HIV and syphilis treatment cost, average years on ART, and
197 time horizon. **Table S1** shows the model parameters, ranges, and distributions used in the sensitivity analysis.

198 **Patient and public involvement**

199 It was not appropriate or possible to involve patients or the public in the design, conduct, reporting, or
200 dissemination plans of our research.

201 202 **RESULTS**

203 Increasing annual HIV test coverage from 50% (baseline) to 75% using an HIV RDT (scenario 1) or a dual RDT
204 (scenario 2) is projected to avert 3,206 HIV infections and 660 AIDS-related deaths by 2035 in Viet Nam (**Table**
205 **3**). Annual testing using dual RDT led to treatment of an additional 27,727 syphilis cases over 15 years compared
206 to using HIV RDT, but the number of HIV infections averted was the same. HIV testing with either HIV or dual
207 RDT biannually (scenarios 3, 4, & 5) was projected to avert an additional 875 HIV infections and 183 AIDS-
208 related deaths by 2035 compared to annual testing. Testing using a dual HIV/syphilis RDT biannually among key
209 populations is projected to lead to an additional 88,401 syphilis cases treated by 2035, compared to annual testing
210 using a dual RDT (88,953 total syphilis cases treated).

Table 3. Estimated HIV and syphilis infections, and cost-effectiveness of increased HIV and Dual HIV/syphilis testing among key populations in Viet Nam from 2020-2035. Each scenario refers to the number of tests per year. The baseline scenario assumes that 50% of key populations are tested for HIV each year and syphilis testing rates are specific to each sub-population (FSW, MSM, and PWID). Scenarios including one test per year assume a 75% test acceptance rate, and those that include two tests per year assume a 75% test acceptance rate for the first test, and a 68.5% test acceptance rate for the second test. *Incremental cases averted*, *Total DALYs averted*, and *ICERs* compare each scenario to the previous one.

		Scenario					
		Baseline	1 Dual Test	1 HIV Test	1 HIV & 1 Dual	2 HIV Tests	2 Dual Tests
HIV	New HIV infections	57,902	54,696	54,696	53,821	53,821	53,821
	AIDS deaths	13,877	13,217	13,217	13,034	13,034	13,034
	Total HIV DALYs	174,567,240	174,508,007	174,508,007	174,490,608	174,490,608	174,490,608
Syphilis	Total cases treated	88,953	116,680	88,953	116,680	88,953	177,354
	Total DALYs treated	2,831	3,713	2,831	3,713	2,831	5,644
Incremental cases averted	HIV infections averted	-	3,206	0	875	0	0
	HIV DALYs averted	-	59,233	0	17,399	0	0
	Syphilis cases treated	-	27,727	-27,727	27,727	-27,727	88,401
	Syphilis DALYs averted	-	882	-882	882	-882	2,813
Total DALYs averted (HIV & Syphilis)		-	60,115	-882	18,281	-882	2,813
Costs (USD)	Net Costs	\$31,036,672	\$31,659,182	\$33,094,783	\$51,942,954	\$53,378,555	\$62,896,039
	HIV testing	\$16,491,955	-	\$24,683,204	\$22,142,027	\$46,825,230	-
	HIV treatment averted	-	-\$6,133,138	-\$6,133,138	-\$7,991,393	-\$7,991,393	-\$7,991,393
	Syphilis testing	\$14,084,698	\$1,535,409	\$14,084,698	\$1,535,409	\$14,084,698	\$2,333,826
	Syphilis treatment	\$460,019	\$603,395	\$460,019	\$603,395	\$460,019	\$917,162
	Dual testing	-	\$35,653,516	-	\$35,653,516	-	\$67,636,444
Total incremental costs		-	\$622,510	\$1,435,601	\$18,848,171	\$1,435,601	\$9,517,484
ICERs (cost per DALY averted)		-	\$10	<i>Dom</i>	\$1,166	<i>Dom</i>	\$5,672

*DALY=disability adjusted life-years, USD=United States dollars, ICERs=incremental cost-effectiveness ratios, FSW=female sex workers, MSM=men who have sex with men, PWID=people who inject drugs

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The most effective strategy was biannual testing among MSM, PWID, and FSW with the dual RDT, which was projected to avert 4,081 HIV infections (7% of total infections), 76,632 HIV DALYs (0.04% of total HIV DALYs), and treat 88,401 cases of syphilis by 2035 compared to the baseline scenario. The discounted cost of implementing this scenario over 30 years is \$62.9 million USD compared to \$31.0 million USD for the baseline scenario. The testing cost of implementing biannual testing using the dual RDT is approximately four times the cost of baseline testing with an HIV RDT (\$67.6 million vs. \$16.5 million, respectively), but an estimated \$8.0 million USD in HIV treatment costs would be averted by biannual HIV testing, and \$11.8 million USD in syphilis testing costs would be averted by using the dual RDT. The cost of biannual testing with an HIV RDT and continuing to test for syphilis with RPR is higher than biannual testing with one dual RDT and one HIV RDT (\$53.4 vs. \$51.9 million USD, respectively), but using one dual test in biannual testing treats an estimated 28,000 more cases of syphilis over 15 years while averting the same number of HIV cases.

Annual testing with the dual RDT is cost-effective compared to the baseline scenario (\$10 USD per DALY averted) (**Figure 1**). Annual HIV testing with HIV RDT is more expensive and averts fewer DALYs than with the dual RDT (strongly dominated). The next most efficient scenario is biannual testing using one dual RDT and one HIV RDT, which is cost-effective (\$1,166 USD per DALY averted). Biannual testing with HIV RDT is less effective and more costly than biannual testing using one dual RDT and one HIV RDT, while biannual testing using the dual RDT provides additional health benefits but is not cost-effective (\$5,672 USD per DALY averted). Despite slightly higher initial costs, the discounted cost of annual testing with a dual RDT becomes less than that of current testing within two years, due to decreased ART costs associated with HIV averted (**Figure S2**).

Sensitivity analyses including all scenarios found that an annual dual RDT (scenario 2) is cost-saving in 52% of the simulations and either cost-saving or cost-effective (at \$2,715 per DALY averted) in all

1
2
3 242 simulations (**Table S2**). Biannual testing using one dual RDT and one HIV RDT was cost-effective in
4
5 243 86% of simulations, but cost-saving in only 1% of simulations (**Figure 2**). Biannual testing using two dual
6
7
8 244 RDTs was cost-effective in 45% of simulations and cost-saving in 31% of simulations as compared to
9
10 245 biannual testing with one dual RDT and one HIV RDT. In univariate sensitivity analysis adjusting costs,
11
12 246 our scenarios that involve one dual RDT (scenarios 2 and 3) remain cost-effective even after all costs
13
14
15 247 (testing and treatment) are increased by 50% (\$16 and \$1,705 USD per DALY averted respectively).
16
17
18 248

19 20 249 **DISCUSSION**

21
22
23 250 In this modeling analysis we found that implementing annual testing among key populations with the dual
24
25 251 RDT at 75% coverage was cost-effective, averted more HIV infections, and treated more syphilis cases
26
27 252 compared to annual testing using HIV RDT at 50% coverage and current syphilis testing in Viet Nam.
28
29 253 While biannual testing with one dual RDT and one HIV RDT was projected to be more costly, it would
30
31
32 254 avert more HIV and syphilis related DALYs, and using dual RDT for both tests would avert additional
33
34 255 DALYs attributed to syphilis, although this latter scenario was not found to be cost-effective. Increasing
35
36 256 the frequency of HIV testing to one or two tests per year using only HIV RDTs (scenario 1 & 4), while
37
38
39 257 continuing to screen for syphilis using RPR, was not efficient compared to other strategies.
40

41
42 258 Implementing biannual testing substantially increases testing costs, but also prevents more HIV infections,
43
44 259 therefore averting more HIV healthcare costs, including ART and hospitalizations. Increasing test
45
46 260 frequency may be cost-saving or cost-effective, although it incurs considerable costs in the near term while
47
48 261 costs averted may not be observed for many years. Annual testing using a dual RDT can help offset some
49
50
51 262 near-term costs as it is less expensive than using HIV RDT and syphilis RPR. Policymakers must weigh
52
53 263 the health impact and cost-effectiveness of different testing scenarios over time against current
54
55
56
57
58
59

1
2
3 264 affordability; however, using the dual RDT will help integrate syphilis testing within existing HIV testing
4
5 265 programs, improving program efficiencies.[27]
6
7

8 266 Implementation of dual RDT is occurring in some settings; preliminary reports indicate that 49 countries
9
10 267 have adopted policies to use dual HIV/syphilis RDT in ANC, and 15% of reporting counties have policies
11
12 to support their use in key populations, although the extent of implementation is unknown.[28] The
13 268
14
15 269 President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund both fund dual RDT in
16
17 270 ANC,[29] and there are multiple dual RDTs prequalified by the WHO.[30] The use of dual RDT during
18
19
20 271 ANC could be a model for improving HIV/STI integration, particularly among those at high risk for both
21
22 272 HIV and syphilis, such as key populations, however, there are operational challenges associated with
23
24 273 integrating HIV and STI programs and delivering person-centered diagnosis, treatment, and prevention
25
26
27 274 services.[31]
28

29 275 Benefits of the dual test are its potential to cost-effectively reach more at-risk individuals at the point-of-
30
31 care. Annual or biannual testing can enable earlier identification of HIV-positive individuals for faster
32 276
33
34 277 ART initiation and prevention of onward transmission. Annual HIV testing for key populations is
35
36 278 recommended by WHO, and more frequent testing (every 3-6 months) may be advised for those with
37
38
39 279 individual risk factors, including those using pre-exposure prophylaxis (PrEP) and key populations
40
41 280 presenting with STIs.[23] Individuals presenting with syphilis symptoms should also test for HIV, and
42
43 281 using the dual RDT is less costly as compared to a syphilis RPR and HIV RDT. As policymakers scale up
44
45
46 282 PrEP among key populations in Viet Nam, including at least one dual RDT in the testing algorithm may
47
48 283 be more cost-effective than using HIV RDTs alone. In addition, using dual RDT tests can facilitate lay
49
50 284 providers to offer both HIV and syphilis testing for their community.[32]
51
52

53 285 Our results were robust to sensitivity analyses, suggesting that testing annually or biannually using dual
54
55 286 RDTs remains cost-effective if testing costs increase and HIV prevalence decreases. In scenarios
56
57
58
59
60

1
2
3 287 involving dual RDT, the majority (>98%) of benefits, as measured in DALYs, come from averting HIV
4
5 288 infections rather than treating syphilis due to the relatively large burden of disease from HIV compared to
6
7
8 289 syphilis. However, since the cost of a dual RDT is only slightly higher than the cost of an HIV RDT, it is
9
10 290 cheaper to use a dual RDT than separate HIV RDT and syphilis RPR tests in situations where both tests
11
12 291 are recommended.

14
15 292 Increased HIV testing can reduce HIV-associated morbidity and mortality and transmission from PLHIV
16
17 293 through early detection and initiation of ART. While models suggest high ART coverage would result in
18
19
20 294 substantial declines in HIV incidence,[33, 34] empiric data from countries with population-level viral
21
22 295 suppression exceeding 73% (e.g. Australia, eSwatini, and Thailand) have observed less significant
23
24 296 reductions in HIV incidence relative to predictions from mathematical models.[35] Similarly, when high
25
26
27 297 ART coverage was achieved in a series of cluster-randomized trials in sub-Saharan Africa, it resulted in
28
29 298 decreased population-level HIV incidence; however, this decrease was insufficient to end HIV as a public
30
31 299 health threat.[36–39] These discrepancies may in part be attributed to delayed diagnosis and ART
32
33
34 300 initiation following infection,[40, 41] and gaps in the 95-95-95 targets for some population groups, for
35
36 301 example young men and key populations. Additional barriers may include poor coverage of evidence-
37
38 302 based prevention interventions and persistent structural barriers, particularly for key populations. More
39
40
41 303 frequent HIV testing strategies could increase earlier diagnosis and initiation on ART and focusing testing
42
43 304 and linkage efforts on key populations could reduce the access and coverage disparities in these groups.
44
45 305 However, more frequent testing will also increase program costs, not only through additional commodity
46
47 306 procurement but also for health systems, program coordination, and outreach. Policymakers may likely
48
49
50 307 benefit from targeting limited testing resources towards high-risk groups such as key populations.

51
52 308 Dual RDTs may also increase syphilis testing frequency and coverage among key populations who are
53
54
55 309 more likely to access HIV testing than testing for syphilis. Previous research has shown that coupling
56
57
58
59
60

1
2
3 310 rapid syphilis testing in ANC may also increase HIV test coverage in LMICs, particularly in settings where
4
5 311 HIV test coverage is low.[42] This strategy may be similarly effective at increasing test coverage for both
6
7
8 312 diseases among key populations, as well as augment current ANC testing by reaching women in key
9
10 313 populations who present late or are missed by ANC services. While there is a lack of data on dual RDTs
11
12 314 among key populations, models of dual RDT during ANC have been shown to be cost-saving or cost-
13
14
15 315 effective among both key populations and the general population of pregnant women.[7, 43] While dual
16
17 316 RDTs are likely more effective in the context of ANC since testing can avert more adverse outcomes
18
19 317 associated with congenital syphilis and mother-to-child HIV transmission, we find dual RDTs may also
20
21
22 318 be cost-effective among non-pregnant key populations.

23
24 319 Our results are consistent with previously published models that show expanded testing and early access
25
26
27 320 to ART for key populations in Viet Nam will cost-effectively reduce the country's HIV burden.[44, 45]
28
29 321 Additionally, models from both low- and high-resource countries suggest HIV testing every 3-6 months
30
31 322 among key populations can be cost-effective in concentrated epidemics.[46, 47] However, HIV risk within
32
33
34 323 key populations is not homogenous; further targeting of higher-risk groups within key populations may
35
36 324 be needed to achieve efficient testing regimens. While we examine the impact of increased testing
37
38 325 frequency among key populations as a whole, previous research has described the benefits of targeting
39
40
41 326 high-risk groups within key populations.[48] Individuals who engage in risky behaviors, such as those
42
43 327 with more sexual partners, practicing unprotected sex, or needle/syringe sharing may benefit from
44
45 328 additional testing or linkage to HIV prevention such as PrEP and harm reduction interventions. Further
46
47 329 research is needed on the optimal testing intervals for higher-risk groups of key populations.

49
50 330 Globally, approximately one-third of key populations are not aware of their HIV status. Programs focusing
51
52
53 331 on HIV testing and treatment among FSW and PWID in Viet Nam have shown success in reducing HIV
54
55 332 prevalence in these groups; however, less than a third of MSM reported testing for HIV in 2015, likely

1
2
3 333 contributing to increases in HIV prevalence among this group in the past decade.[49] Annual syphilis
4
5 334 testing among key populations in Viet Nam is similarly low, ranging from 16% among PWID to 36%
6
7
8 335 among FSW.[18–20] Due to high dual prevalence of HIV and syphilis among key populations, dual testing
9
10 336 is a promising strategy to increase testing coverage and linkage to care.

11
12
13 337 Our analysis has several limitations. We did not include the cost of scaling-up and training providers in
14
15 338 administering dual RDTs. However, RDT are easy to use and can be administered by a lay provider, and
16
17 339 rapid results can minimize loss to follow-up. Overall, dual RDTs have been shown to have adequate
18
19
20 340 performance in field settings in Viet Nam among key populations.[50] Dual RDTs may also increase HIV
21
22 341 test coverage as they can be easily conducted by community health workers outside of healthcare settings,
23
24 342 and they may be more acceptable to some members of key populations who are concerned about stigma
25
26
27 343 associated with testing.[51] Dual RDTs may also expand syphilis testing uptake, as most syphilis cases in
28
29 344 Viet Nam are currently diagnosed at provincial hospitals. Despite this, some additional training,
30
31 345 supervision, and support will be needed to scale-up dual RDT use among key populations.

32
33
34 346 We did not explicitly model HIV testing or diagnosis in this analysis as HIV testing uptake is not an
35
36 347 adjustable model parameter in Spectrum. We instead modeled ART coverage, which required assumptions
37
38
39 348 about the link between testing frequency and ART coverage. Since data on the impact of retesting on
40
41 349 population HIV incidence is limited, we made conservative assumptions about the frequency of linkage
42
43 350 to care and ART use following retesting. We assumed that HIV testing frequency would increase in Viet
44
45
46 351 Nam among key populations in the baseline scenario but testing frequency would increase more quickly
47
48 352 under the other scenarios. Because of this, we believe our estimates of the impact of increased testing
49
50 353 frequency are conservative. Due to the lack of evidence on the impact of retesting on population HIV
51
52 354 incidence, a model that explicitly includes testing rates as a parameter would also need to rely on
53
54
55 355 assumptions concerning the relationship between testing behavior and ART enrollment.

1
2
3 356 Some model assumptions regarding the timing of HIV and syphilis testing may be inaccurate. Timing of
4
5 357 testing is an important component from both a technical analytic perspective and guideline development
6
7
8 358 process. In truth, there are a nearly limitless number of permutations of frequency and spacing of retests.
9
10 359 We chose even spacing as it is easily interpretable at all levels of research, policy, and service delivery.
11
12 360 This maximal spacing between tests is expected to have the largest impact at the population-level,
13
14
15 361 assuming risk is evenly spread across the calendar year. We assume regular testing intervals for the entire
16
17 362 population in each scenario, but it is possible – and entirely sensible – for people who had a risky sexual
18
19 363 encounter or who are experiencing symptoms to seek more frequent retesting than biannually. We
20
21
22 364 assumed in scenarios that included a dual RDT, additional syphilis screening tests would not be conducted.
23
24 365 However, PLWH who know their status and present for syphilis screening do not need an HIV test.
25
26
27 366 We did not include the costs of outreach to achieve increased test coverage of key populations.
28
29 367 Considerable expansions of first time testing among MSM in Viet Nam have recently been achieved
30
31 368 through social media campaigns, perhaps providing a guide for cost-effectively increasing testing uptake
32
33
34 369 among key populations.[49, 52] We also did not consider the burden that increased test coverage and
35
36 370 frequency may have on the health system; however, as testing may be conducted effectively using lay
37
38 371 providers, increased testing may not substantially impact the provision of other services.[51] Although
39
40
41 372 targeting key populations in lower prevalence regions may be more difficult and costly, these results are
42
43 373 robust to increased costs and it will likely remain an effective use of resources. Research that focuses on
44
45 374 province-specific estimates of cost and impact would likely find that focusing on high-burden areas is
46
47 375 more cost-effective; however, health policy, financing, guideline development, and implementation
48
49
50 376 continue to be led nationally in Viet Nam. Therefore, national-level evidence is needed to direct decision
51
52 377 making.
53
54
55
56
57
58
59
60

1
2
3 378 We assume that syphilis screening will not impact syphilis prevalence rates. Increased screening may
4
5 379 reduce prevalence by increasing early treatment, but syphilis screening also has the potential to increase
6
7
8 380 prevalence as individuals with latent syphilis are unlikely to transmit the infection to others unless they
9
10 381 are treated and then infected again. Thus, we believe our estimates of infections averted and cost-
11
12 382 effectiveness are conservative. Finally, there is limited data on population size, HIV and syphilis
13
14
15 383 prevalence, and health seeking behaviors among key populations. We based our model input on estimates
16
17 384 included in published literature as well as Viet Nam country sources.
18
19

20 385 **CONCLUSIONS**

21
22
23 386 Our study suggests that annual or biannual HIV and syphilis testing among key populations in Viet Nam
24
25 387 using a dual RDT will increase HIV and syphilis detection and treatment, while remaining cost-saving or
26
27 388 cost-effective. Integrating HIV and other STI testing can streamline services as well as expand testing and
28
29 389 help countries with epidemics concentrated in key populations reach 95-95-95 targets. Future collection
30
31
32 390 of empirical data, including conducting budget impact studies, would be useful to determine the impact
33
34 391 of HIV and syphilis screening among key populations on ART uptake as well as HIV and syphilis
35
36 392 incidence, particularly in concentrated HIV epidemics.
37
38

39 393 **COMPETING INTERESTS**

40
41
42 394 The authors declare no competing interests.
43
44 395
45

46 396 **FUNDING SOURCE**

47
48
49 397 WHO-USAID: GHA-G-00-09-00003; NIH/NIAID: K01 AI116298
50
51

52 398 **CONTRIBUTORSHIP STATEMENT**

53
54 399 CJ and AD devised the project and the main conceptual ideas. DC, DG, and RB parameterized the model.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

400 DC and DG carried out the model implementation. VN and SVH provided model feedback. All authors,
401 including DC, DG, RB, MS, MBD, MSJ, RB, MNO, VM, VN, SVH, MMT, TEW, CJ, and AD, provided
402 critical feedback and helped shape the research, analysis, and manuscript.

DATA SHARING STATEMENT

Extra data is available by emailing David Coomes, dcoomes@uw.edu

ETHICS APPROVAL

This study did not receive nor require ethics approval as it does not involve human or animal participants.

References

- 1
2
3 407
4
5 408 [1] UNAIDS Joint United Nations Programme on HIV/AIDS. *Global AIDS update 2019 - Communities*
6
7 409 *at the centre*. Geneva, <https://www.unaids.org/en/resources/documents/2019/2019-global->
8
9 410 *AIDS-update (2019)*.
- 10
11 411 [2] UNAIDS Joint United Nations Programme on HIV/AIDS. *Global AIDS Update 2020: Seizing the*
12
13 412 *moment*. Geneva, <https://www.unaids.org/en/resources/documents/2020/global-aids-report>
14
15 413 *(2020)*.
- 16
17 414 [3] Cameron CE. Syphilis Vaccine Development: Requirements, Challenges, and Opportunities. *Sex*
18
19 415 *Transm Dis* 2018; 45: S17.
- 20
21 416 [4] Tsuboi M, Evans J, Davies E, et al. Prevalence of syphilis among men who have sex with men: A
22
23 417 global systematic review and meta-analysis from 2000 to 2020. *Lancet Glob Heal*; In press.
- 24
25
26 418 [5] World Health Organization. *Consolidated guidelines on HIV testing services*. Geneva,
27
28 419 <https://www.ncbi.nlm.nih.gov/books/NBK316021/> (2015).
- 29
30 420 [6] World Health Organization. *WHO Guideline on Syphilis screening and treatment for pregnant*
31
32 421 *women*, [https://www.who.int/reproductivehealth/publications/rtis/syphilis-ANC-](https://www.who.int/reproductivehealth/publications/rtis/syphilis-ANC-screenandtreat-guidelines/en/)
33
34 422 *screenandtreat-guidelines/en/* (2017).
- 35
36 423 [7] Rodriguez P, Roberts DA, Meisner J, et al. Cost-effectiveness of dual maternal HIV and syphilis
37
38 424 testing strategies in high and low HIV prevalence countries: a modeling study. *Lancet Glob Heal*
39
40 425 2021; 9: E61–E71.
- 41
42
43 426 [8] World Health Organization. *Consolidated Guidelines on the Use of Antiretroviral Drugs for*
44
45 427 *Treating and Preventing HIV Infection*. 2016. Epub ahead of print 2016. DOI:
46 428 10.1017/CBO9781107415324.004.
- 47
48
49 429 [9] UNAIDS. *90-90-90 An ambitious treatment target to help end the AIDS epidemic*,
50
51 430 <https://www.unaids.org/en/resources/909090> (2016).
- 52
53 431 [10] Hakim AJ, MacDonald V, Hladik W, et al. Gaps and opportunities: measuring the key population
54
55 432 cascade through surveys and services to guide the HIV response. *J Int AIDS Soc* 2018; 21:

- 1
2
3 433 e25119.
4
5
6 434 [11] World Health Organization. *Global Health Sector Strategy on Sexually Transmitted Infections*
7
8 435 2016-2021, <https://www.who.int/reproductivehealth/publications/rtis/ghss-stis/en/> (2016).
9
10 436 [12] World Health Organization. Global Health Observatory data repository: Data on syphilis,
11
12 437 <https://apps.who.int/gho/data/node.main.A1357STI?lang=en> (accessed 4 June 2020).
13
14 438 [13] Stover J, Brown T, Puckett R, et al. Updates to the Spectrum/Estimations and Projections
15
16 439 Package model for estimating trends and current values for key HIV indicators. *AIDS* 2017; 31:
17
18 440 S5–S11.
19
20 441 [14] Tuite AR, Testa C, Rönn M, et al. Exploring how epidemic context influences syphilis screening
21
22 442 impact: A mathematical modeling study. *Sex Transm Dis*; 47. Epub ahead of print 2020. DOI:
23
24 443 10.1097/OLQ.0000000000001249.
25
26 444 [15] Tuite A, Fisman D. Go big or go home: Impact of screening coverage on syphilis infection
27
28 445 dynamics. *Sex Transm Infect*; 92. Epub ahead of print 2016. DOI: 10.1136/sextrans-2014-052001.
29
30
31 446 [16] Clatts MC, Goldsamt LA, Giang LM, et al. Sexually transmissible infection and HIV prevention and
32
33 447 treatment for young male sex workers in Vietnam: Findings from the SHEATH intervention. *Sex*
34
35 448 *Health*. Epub ahead of print 2016. DOI: 10.1071/SH16051.
36
37 449 [17] Bao A, Colby DJ, Trang T, et al. Correlates of HIV Testing Among Transgender Women in Ho Chi
38
39 450 Minh, Vietnam. *AIDS Behav*. Epub ahead of print 2016. DOI: 10.1007/s10461-016-1574-8.
40
41 451 [18] Justimus P, Colby D, Mai Doan Anh T, et al. Willingness to use the Internet to seek information
42
43 452 on HIV prevention and care among men who have sex with men in Ho Chi Minh City, Vietnam.
44
45 453 *PLoS One* 2013; 8: e71471.
46
47 454 [19] Nguyen TA, Hoang LT, Pham VQ, et al. Risk factors for HIV-1 seropositivity in drug users under 30
48
49 455 years old in Haiphong, Vietnam. *Addiction* 2001; 96: 405–413.
50
51
52 456 [20] Ngo AD, Ratliff EA, Mccurdy SA, et al. Health-seeking behaviour for sexually transmitted
53
54 457 infections and HIV testing among female sex workers in Vietnam. *AIDS Care - Psychol Socio-*
55
56 458 *Medical Asp AIDS/HIV* 2007; 19: 878–887.
57
58
59
60

- 1
2
3 459 [21] Magnani R, Riono P, Nurhayati, et al. Sexual risk behaviours, HIV and other sexually transmitted
4 infections among female sex workers in Indonesia. *Sex Transm Infect*. Epub ahead of print 2010.
5 460 DOI: 10.1136/sti.2009.038059.
6
7 461
8
9 462 [22] Cassini A, Colzani E, Pini A, et al. Impact of infectious diseases on population health using
10 incidence-based disability-adjusted life years (DALYs): Results from the burden of communicable
11 463 diseases in Europe study, European Union and European economic countries, 2009 to 2013.
12 *Eurosurveillance*. Epub ahead of print 2018. DOI: 10.2807/1560-7917.ES.2018.23.16.17-00454.
13 464
14
15 465
16
17 466 [23] World Health Organization. *Consolidated guidelines on HIV testing services*. Geneva,
18 <https://www.who.int/publications/i/item/978-92-4-155058-1> (2019).
19 467
20
21
22 468 [24] Feldman J, Mishra S. What could re-infection tell us about R0? A modeling case-study of syphilis
23 transmission. *Infect Dis Model* 2019; 4: 257–264.
24 469
25
26 470 [25] Edejer TT-T, Baltussen R, Adam T, et al. *Making choices in health: WHO guide to cost*
27 *effectiveness analysis*. World Health Organization, 2003.
28 471
29
30 472 [26] World Bank. World Bank Data: GDP per capita (current US\$) - Vietnam,
31 <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=VN> (accessed 16 December
32 473 2020).
33
34 474
35
36 475 [27] Ong JJ, Fu H, Smith MK, et al. Expanding syphilis testing: a scoping review of syphilis testing
37 interventions among key populations. *Expert Rev Anti Infect Ther* 2018; 16: 423–432.
38 476
39
40
41 477 [28] UNAIDS Joint United Nations Programme on HIV/AIDS, WHO. *Laws and Policies Analytics*.
42
43 478 [29] U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). *PEPFAR 2021 Country and Regional*
44 *Operational Plan (COP/ROP) Guidance for all PEPFAR Countries*, [https://www.state.gov/wp-](https://www.state.gov/wp-content/uploads/2020/12/PEPFAR-COP21-Guidance-Final.pdf)
45 479 [content/uploads/2020/12/PEPFAR-COP21-Guidance-Final.pdf](https://www.state.gov/wp-content/uploads/2020/12/PEPFAR-COP21-Guidance-Final.pdf) (2021).
46
47 480
48
49 481 [30] The Global Fund. *List of HIV Diagnostic test kits and equipments classified according to the*
50 *Global Fund Quality Assurance Policy*,
51 482 https://www.theglobalfund.org/media/5878/psm_productshiv-who_list_en.pdf (2021).
52
53 483
54
55 484 [31] Broyles LN, Boeras D, Peeling RW. Implementation of dual maternal HIV-Syphilis testing: The
56
57
58
59
60

1

2

3 485 devil is in the details. *Lancet Glob Heal* 2021; 9: e595.

4

5

6 486 [32] Nguyen V, Anh L, Thong N, et al. High prevalence of HIV, syphilis and HCV among key

7 487 populations and partners: results from an integrated multiple diseases testing led by community

8

9 488 in Viet Nam. In: *Poster exhibition IAS 2019*. Mexico City, Mexico, 2019.

10

11

12 489 [33] Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral

13

14 490 therapy as a strategy for elimination of HIV transmission: a mathematical model. *Lancet* 2009;

15

16 491 373: 48–57.

17

18 492 [34] Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: Systematic comparison of

19

20 493 mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South

21

22 494 Africa. *PLoS Med*; 9. Epub ahead of print July 2012. DOI: 10.1371/journal.pmed.1001245.

23

24 495 [35] UNAIDS. AIDSinfo | UNAIDS, <https://aidsinfo.unaids.org/> (accessed 27 May 2020).

25

26

27 496 [36] Iwuji CC, Orne-Gliemann J, Larmarange J, et al. Universal test and treat and the HIV epidemic in

28

29 497 rural South Africa: a phase 4, open-label, community cluster randomised trial. *Lancet HIV* 2018;

30

31 498 5: e116–e125.

32

33 499 [37] Makhema J, Wirth KE, Pretorius Holme M, et al. Universal Testing, Expanded Treatment, and

34

35 500 Incidence of HIV Infection in Botswana. *N Engl J Med* 2019; 381: 230–242.

36

37 501 [38] Havlir D V., Balzer LB, Charlebois ED, et al. HIV Testing and Treatment with the Use of a

38

39 502 Community Health Approach in Rural Africa. *N Engl J Med* 2019; 381: 219–229.

40

41 503 [39] Hayes RJ, Donnell D, Floyd S, et al. Effect of Universal Testing and Treatment on HIV Incidence —

42

43 504 HPTN 071 (PopART). *N Engl J Med* 2019; 381: 207–218.

44

45 505 [40] Akullian A, Bershteyn A, Jewell B, et al. The missing 27%. *AIDS* 2017; 31: 2427–2429.

46

47 506 [41] Abdool Karim SS. HIV-1 Epidemic Control — Insights from Test-and-Treat Trials. *N Engl J Med*

48

49 507 2019; 381: 286–288.

50

51 508 [42] Swartzendruber A, Steiner RJ, Adler MR, et al. Introduction of rapid syphilis testing in antenatal

52

53 509 care: A systematic review of the impact on HIV and syphilis testing uptake and coverage. *Int J*

54

55

56

57

58

59

60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Gynecol Obstet 2015; 130: S15–S21.

- [43] Gliddon HD, Peeling RW, Kamb ML, et al. A systematic review and meta-analysis of studies evaluating the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. *Sex Transm Infect* 2017; 93: S3–S15.
- [44] Kato M, Long NH, Duong BD, et al. Enhancing the Benefits of Antiretroviral Therapy in Vietnam: Towards Ending AIDS. *Curr HIV/AIDS Rep* 2014; 11: 487–495.
- [45] Kato M, Granich R, Bui DD, et al. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: Towards elimination of HIV transmission. *J Acquir Immune Defic Syndr*. Epub ahead of print 2013. DOI: 10.1097/QAI.0b013e31829b535b.
- [46] Kazemian P, Costantini S, Kumarasamy N, et al. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. *Clin Infect Dis* 2020; 70: 633–642.
- [47] Cipriano LE, Zaric GS, Holodniy M, et al. Cost Effectiveness of Screening Strategies for Early Identification of HIV and HCV Infection in Injection Drug Users. *PLoS One* 2012. DOI: 10.1371/journal.pone.0045176.
- [48] Reitsema M, Steffers L, Visser M, et al. Cost-Effectiveness of Increased HIV Testing among MSM in The Netherlands. *AIDS* 2019; 33: 1807–1817.
- [49] Green KE, Vu BN, Phan HT, et al. From conventional to disruptive: upturning the HIV testing status quo among men who have sex with men in Vietnam. *J Int AIDS Soc* 2018; 21: e25127.
- [50] Withers K, Bristow C, Nguyen M, et al. A field evaluation of a rapid dual immunoassay for human immunodeficiency virus and syphilis antibodies, Hanoi, Vietnam. *Int J STD AIDS* 2019; 30: 173–180.
- [51] Vu BN, Green KE, Phan HTT, et al. Lay provider HIV testing: A promising strategy to reach the undiagnosed key populations in Vietnam. *PLoS One* 2018; 13: e0210063.
- [52] Nguyen VTT, Phan HTT, Kato M, et al. Community-led HIV testing services including HIV self-testing and assisted partner notification services in Vietnam: lessons from a pilot study in a

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

536 concentrated epidemic setting. *J Int AIDS Soc* 2019; 22: e25301.

For peer review only

1
2
3 538 **FIGURE LEGENDS**
4

5 539 **Figure 1. Efficiency frontier presenting the total disability adjusted life years (DALYs) and costs for**
6 540 **five testing scenarios among key populations.** The solid line indicates the scenarios that are not
7 541 dominated by other scenarios. Dominated indicates that a scenario is either more costly and less effective
8 542 or has a higher ICER than a scenario that is more effective. The ICERs for the non-dominated scenarios
9 543 are shown. DALYs=disability adjusted life-years, ICER=incremental cost-effectiveness ratio, RDT=rapid
10 544 diagnostic test, USD=United States dollars

12 545
13
14 546
15
16 547
17 548 **Figure 2. Sensitivity analysis of non-dominated scenarios using a Monte Carlo simulation of the**
18 549 **cost effectiveness of HIV/syphilis dual testing among key populations in Viet Nam.** Plot shows 10,000
19 550 iterations in which 17 key parameters were randomly adjusted. All points below the green line are cost-
20 551 effective at \$2,715 per DALY averted and those below the solid black line (y-intercept) are cost-saving.
22 552 Only non-dominated scenarios are shown in this figure; cost-effectiveness of *1 Dual Test* is compared to
23 553 baseline, *1 HIV Test & 1 Dual Test* is compared to *1 Dual Test*, and *2 Dual Tests* is compared to *1 HIV*
24 554 *Test & 1 Dual Test*. DALYs=disability adjusted life-years, ICER=incremental cost-effectiveness ratio,
25 555 RDT=rapid diagnostic test, USD=United States dollars.
26

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Efficiency frontier presenting the total disability adjusted life years (DALYs) and costs for five testing scenarios among key populations. The solid line indicates the scenarios that are not dominated by other scenarios. Dominated indicates that a scenario is either more costly and less effective or has a higher ICER than a scenario that is more effective. The ICERs for the non-dominated scenarios are shown. DALYs=disability adjusted life-years, ICER=incremental cost-effectiveness ratio, RDT=rapid diagnostic test, USD=United States dollars

2116x1058mm (72 x 72 DPI)




Figure 2. Sensitivity analysis of non-dominated scenarios using a Monte Carlo simulation of the cost effectiveness of HIV/syphilis dual testing among key populations in Viet Nam. Plot shows 10,000 iterations in which 17 key parameters were randomly adjusted. All points below the green line are cost-effective at \$2,715 per DALY averted and those below the solid black line (y-intercept) are cost-saving. Only non-dominated scenarios are shown in this figure; cost-effectiveness of 1 Dual Test is compared to baseline, 1 HIV Test & 1 Dual Test is compared to 1 Dual Test, and 2 Dual Tests is compared to 1 HIV Test & 1 Dual Test. DALYs=disability adjusted life-years, ICER=incremental cost-effectiveness ratio, RDT=rapid diagnostic test, USD=United States dollars.

2116x1058mm (72 x 72 DPI)

1
2
3 **Cost-effectiveness of implementing HIV and HIV/syphilis dual testing among key**
4 **populations in Viet Nam: a modeling analysis**
5

6
7 **Supplemental material**
8

9
10
11 Table S1: Parameters and probability distributions for Monte Carlo simulation

12
13 Table S2: Sensitivity analysis of all scenarios using a Monte Carlo simulation

14
15 Figure S1: Estimated yearly HIV incidence under baseline, annual, and biannual HIV testing

16
17 Figure S2: Cost pressure analysis of testing scenarios
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table S1. Parameters and probability distributions for Monte Carlo simulation. Table shows the baseline model parameter values and the probability distributions used for random draws of 17 variables for 10,000 Monte Carlo simulations. Beta distributions were used for all proportion parameters. For the beta distribution, the alpha and beta parameters were calculated as the baseline value multiplied by 100, except for the *impact* parameter where an alpha and beta of 25 was used. Gamma distributions were used for all other parameters. For the gamma distribution, the alpha parameter was calculated as the square of the baseline parameter divided by the square of the standard deviation. The beta parameter was calculated as the square of the standard deviation divided by the baseline parameter.

Model Parameter	Baseline value	Distribution	St. Dev	alpha/beta
Baseline HIV test acceptance	50%	Beta	N/A	50
Recommended test acceptance	75%	Beta	N/A	75
Additional test drop off rate	10%	Beta	N/A	10
HIV Lay Test Cost	\$4.50	Gamma	\$3.00	N/A
Syphilis RPR1 Cost	\$6.28	Gamma	\$3.50	N/A
Syphilis TPHA Cost	\$10.26	Gamma	\$5.00	N/A
HIV/Syphilis Dual Test Cost	\$6.50	Gamma	\$3.50	N/A
ART Treatment Cost	\$285	Gamma	\$50	N/A
Syphilis Treatment Cost	\$6.50	Gamma	\$3.50	N/A
Avg Years on ART	25	Gamma	3	N/A
Time Horizon	2035	Gamma	3	N/A
Impact	100%	Beta	N/A	25
Baseline Syphilis test acceptance FSW	35%	Beta	N/A	35
Baseline syphilis test acceptance MSM	27%	Beta	N/A	27
Baseline syphilis test acceptance PWID	16%	Beta	N/A	16
Baseline syphilis prevalence FSW	2.1%	Beta	N/A	2.1
Baseline syphilis prevalence MSM	6.7%	Beta	N/A	6.7
Baseline syphilis prevalence PWID	0.3%	Beta	N/A	0.3

Table S2. Sensitivity analysis of all scenarios using a Monte Carlo simulation. Table shows the percentage of simulations (10,000 iterations) in which each scenario is cost-effective (at \$500 or \$2,715 per DALY averted), cost-saving, or less-effective. Less effective scenarios are both less effective and more costly as compared to the scenario above. Scenarios are arranged in order of increasing cost and each scenario is compared to the one immediately above; 1 Dual HIV/syphilis RDT is compared to the baseline scenario.

Scenario	Cost-effective	Cost-effective	Cost-saving	Less effective
	(\$500)	(\$2,715)		
1 Dual HIV/syphilis RDT	85%	100%	52%	0%
1 HIV RDT	1%	1%	1%	98%
1 Dual HIV/syphilis RDT & 1 HIV RDT	32%	84%	18%	0%
2 HIV RDTs	1%	1%	1%	98%
2 Dual HIV/syphilis RDTs	45%	52%	44%	0%

DALY=disability adjusted life-year, RDT=rapid diagnostic test

Figure S1. Estimated yearly HIV incidence under baseline, annual, and biannual HIV testing.

Figure shows modeled incidence under each scenario for the entire adult population of Viet Nam. The baseline scenario assumes 95% ART coverage among PLWH by 2028 (4.8% increase per year). Annual HIV testing models a 6.0% ART coverage increase per year, and biannual testing models a 7.2% ART coverage increase per year. Maximum test coverage is 95% for each model. All models assume ART coverage of 66% of men and 72% of women living with HIV in 2020. Scenarios are implemented in 2020 and modeled through 2035.





Figure S2. Cost pressure analysis of testing scenarios. Figure shows the discounted cost over time of each scenario. Costs are discounted 3% with a time horizon from 2020 – 2035. Baseline costs include testing costs assuming that 50% of key populations are tested for HIV each year and syphilis testing rates are specific to each sub-population (FSW, MSM, and PWID), and syphilis treatment costs. All other scenarios include the cost of HIV treatment averted compared to the baseline scenario, testing costs, and syphilis treatment costs. Scenarios including one test per year assume a 75% test acceptance rate, and those that include two tests per year assume a 75% test acceptance rate for the first test, and a 68.5% test acceptance rate for the second test. Each scenario refers to the number of tests per year. RDT=rapid diagnostic test, USD=United States dollars



CHEERS Checklist

Items to include when reporting economic evaluations of health interventions

The **ISPOR CHEERS Task Force Report**, *Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force*, provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

Section/item	Item No	Recommendation	Reported on page No/line No
Title and abstract			
Title	1	Identify the study as an economic evaluation or use more specific terms such as “cost-effectiveness analysis”, and describe the interventions compared.	Line 1
Abstract	2	Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.	Page 2
Introduction			
Background and objectives	3	Provide an explicit statement of the broader context for the study. Present the study question and its relevance for health policy or practice decisions.	Page 4
Methods			
Target population and subgroups	4	Describe characteristics of the base case population and subgroups analysed, including why they were chosen.	Page 4 - 5
Setting and location	5	State relevant aspects of the system(s) in which the decision(s) need(s) to be made.	Page 4
Study perspective	6	Describe the perspective of the study and relate this to the costs being evaluated.	Page 6-7
Comparators	7	Describe the interventions or strategies being compared and state why they were chosen.	Page 7
Time horizon	8	State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.	Line 165
Discount rate	9	Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.	Line 166
Choice of health outcomes	10	Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.	Line 164
Measurement of effectiveness	11a	<i>Single study-based estimates:</i> Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.	NA



1		11b	<i>Synthesis-based estimates:</i> Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.	Page 6
2				
3				
4	Measurement and	12	If applicable, describe the population and methods used to elicit preferences for outcomes.	Line 110
5	valuation of preference			
6	based outcomes			
7				
8	Estimating resources	13a	<i>Single study-based economic evaluation:</i> Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	NA
9	and costs			
10				
11				
12				
13				
14				
15		13b	<i>Model-based economic evaluation:</i> Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.	Page 6
16				
17				
18				
19				
20				
21				
22	Currency, price date,	14	Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.	Page 6
23	and conversion			
24				
25				
26				
27				
28	Choice of model	15	Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.	Page 6
29				
30				
31	Assumptions	16	Describe all structural or other assumptions underpinning the decision-analytical model.	Page 7-8
32				
33				
34	Analytical methods	17	Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.	Page 8
35				
36				
37				
38				
39				
40				
41				
42	Results			
43	Study parameters	18	Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.	Table 1
44				
45				
46				
47				
48				
49	Incremental costs and	19	For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.	Table 3
50	outcomes			
51				
52				
53	Characterising	20a	<i>Single study-based economic evaluation:</i> Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact	NA
54	uncertainty			
55				
56				
57				
58				
59				
60				

1		of methodological assumptions (such as discount rate, study	
2		perspective).	
3			
4	20b	<i>Model-based economic evaluation</i> : Describe the effects on the	
5		results of uncertainty for all input parameters, and uncertainty	
6		related to the structure of the model and assumptions.	Page 10
7	Characterising	21	
8	heterogeneity		
9		If applicable, report differences in costs, outcomes, or cost-	
10		effectiveness that can be explained by variations between	
11		subgroups of patients with different baseline characteristics or	
12		other observed variability in effects that are not reducible by	NA
13		more information.	
14	Discussion		
15	Study findings,	22	
16	limitations,		
17	generalisability, and		
18	current knowledge		Page 10-14
19		Summarise key study findings and describe how they support	
20	Other		
21	Source of funding	23	
22			
23		Describe how the study was funded and the role of the funder	
24		in the identification, design, conduct, and reporting of the	
25		analysis. Describe other non-monetary sources of support.	Page 14
26	Conflicts of interest	24	
27			
28		Describe any potential for conflict of interest of study	
29		contributors in accordance with journal policy. In the absence	
30		of a journal policy, we recommend authors comply with	
31		International Committee of Medical Journal Editors	
32		recommendations.	Page 14

For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT statement checklist

The **ISPOR CHEERS Task Force Report** provides examples and further discussion of the 24-item CHEERS Checklist and the CHEERS Statement. It may be accessed via the *Value in Health* link or via the ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices webpage: <http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>

The citation for the CHEERS Task Force Report is:

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. *Value Health* 2013;16:231-50.

